-
PDF
- Split View
-
Views
-
Cite
Cite
Haran Burri, Christoph Starck, Angelo Auricchio, Mauro Biffi, Mafalda Burri, Andre D’Avila, Jean-Claude Deharo, Michael Glikson, Carsten Israel, Chu-Pak Lau, Christophe Leclercq, Charles J Love, Jens Cosedis Nielsen, Kevin Vernooy, Reviewers:, Nikolaos Dagres, Serge Boveda, Christian Butter, Eloi Marijon, Frieder Braunschweig, Georges H Mairesse, Marye Gleva, Pascal Defaye, Francesco Zanon, Nestor Lopez-Cabanillas, Jose M Guerra, Vassilios P Vassilikos, Mario Martins Oliveira, EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS), EP Europace, Volume 23, Issue 7, July 2021, Pages 983–1008, https://doi.org/10.1093/europace/euaa367
- Share Icon Share
Abstract
With the global increase in device implantations, there is a growing need to train physicians to implant pacemakers and implantable cardioverter-defibrillators. Although there are international recommendations for device indications and programming, there is no consensus to date regarding implantation technique. This document is founded on a systematic literature search and review, and on consensus from an international task force. It aims to fill the gap by setting standards for device implantation.
Introduction
Scope of the document
According to the 2017 European Heart Rhythm Association (EHRA) white book, pacemaker (PM) implantations have increased by 20% and implantable cardioverter-defibrillator (ICD) by 44% over a 10-year period in the European Society of Cardiology (ESC) member countries.1 Therefore, there is a growing need to train device implanters. Proper training in implantation technique results in improved patient outcome, as demonstrated by lower rates of in-hospital2,3 and long-term4 complications in procedures performed by electrophysiologists compared to other specialties. The core curriculum for the heart rhythm specialist5 and the EHRA certification exam provide a framework for required training duration, procedural volume, and knowledge assessment, but do not specifically address proficiency in device implantation technique. An EHRA survey on preferred tools and techniques for implantation of cardiac electronic devices showed considerable heterogeneity in practices across Europe.6 There is, therefore, an unmet need to define best practice for device implantation. The aim of this document is to provide up-to-date recommendations for optimal implantation technique of standard PMs and ICDs, based upon published evidence and expert consensus, in order to provide guidance for training and clinical practice, and ultimately to improve patient outcome. Specific domains, such as leadless pacing, conduction system pacing, cardiac resynchronization therapy (CRT), sub-cutaneous ICDs, and device therapy in children and patients with congenital heart disease are not covered here.
Methodology
This EHRA consensus document is based on a systematic literature search and review. M.B. searched PubMed, Embase, Web of Science, and Cochrane electronic databases for full-text original articles and case reports in English language published between 1 January 2000 and 20 March 2020 relating to transvenous PM and ICD implantation. Additional references were hand-searched and retrieved by checking reference lists by H.B. and C.S. From 4108 retrieved articles uploaded to the Covidence platform (Melbourne, Australia), 477 articles were finally selected by H.B. and C.S. (for details see Supplementary material online, Appendix).
Recommendations are based upon strength of evidence and consensus as outlined in Table 1. All recommendations were subjected to voting and required at least 75% agreement to reach consensus for green and red hearts.
Consensus statement . | Definition . | Symbol . |
---|---|---|
Recommended/indicated or ‘should do this’ | Scientific evidence that a treatment or procedure is beneficial and effective, or is strongly supported by authors’ consensus. | ![]() |
May be used or recommended | General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure | ![]() |
Should NOT be used and is NOT recommended | Scientific evidence or general agreement not to use or recommend a treatment or procedure | ![]() |
Consensus statement . | Definition . | Symbol . |
---|---|---|
Recommended/indicated or ‘should do this’ | Scientific evidence that a treatment or procedure is beneficial and effective, or is strongly supported by authors’ consensus. | ![]() |
May be used or recommended | General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure | ![]() |
Should NOT be used and is NOT recommended | Scientific evidence or general agreement not to use or recommend a treatment or procedure | ![]() |
Evidence: E, expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statement . | Definition . | Symbol . |
---|---|---|
Recommended/indicated or ‘should do this’ | Scientific evidence that a treatment or procedure is beneficial and effective, or is strongly supported by authors’ consensus. | ![]() |
May be used or recommended | General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure | ![]() |
Should NOT be used and is NOT recommended | Scientific evidence or general agreement not to use or recommend a treatment or procedure | ![]() |
Consensus statement . | Definition . | Symbol . |
---|---|---|
Recommended/indicated or ‘should do this’ | Scientific evidence that a treatment or procedure is beneficial and effective, or is strongly supported by authors’ consensus. | ![]() |
May be used or recommended | General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure | ![]() |
Should NOT be used and is NOT recommended | Scientific evidence or general agreement not to use or recommend a treatment or procedure | ![]() |
Evidence: E, expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
General considerations
Preoperative preparation
As a first step, it is important to re-evaluate the indication and to perform a risk-benefit analysis for every patient. This requires a full medical history, review of laboratory results and imaging studies, and knowing current guidelines. A list of elements to consider is shown in Table 2.
History |
Symptoms |
Hobbies (e.g. hunting etc.)/profession (risk of trauma, lead crush, EMI, special permits etc.) |
Medication (anticoagulants, antiplatelet drugs etc.) |
For replacements/revisions/upgrades: connector types, venous obstruction |
Comorbidities (diabetes → adapt insulin dose, early timing of procedure; prior chest radiotherapy,236 treatment of breast cancer,236,237 haemodialysis → contralateral implantation; dementia → measures for wound care; COPD → prudent oxygen administration due to risk of hypercapnia; presence of indwelling catheters or pacing leads, history of cardiac surgery, history of previous CIED infection, etc.) |
Evaluation of patients concerns and preferences (e.g. cosmetic aspects) |
Requirement for MRI-conditionality (including 1.5 T or 3 T conditionality) |
Allergies (antibiotics, iodine, device components e.g. silicone, titanium,238–241 etc.) |
Drug intolerance (opiates, sedatives) |
Test results |
Blood tests (haematology, INR if on VKA, renal function, electrolytes) |
ECG (underlying rhythm; LBBB → risk of traumatic heart block or requirement for CRT) |
Holter if available (sinus function, AV conduction disease) |
Exercise test if available (exercise capacity, chronotropic incompetence, atrioventricular conduction) |
View echocardiogram images if available (LVEF, chamber size, evidence of PLSVC with dilated CS, severe tricuspid regurgitation) |
Chest X-ray if available (morphological abnormalities, for comparison with post-operative X-ray) |
Other considerations |
Timing (fasting in diabetic patients, dialysis etc.) |
Required skills/experience of the operator |
Availability of required material and adequate fluoroscopy |
Availability of required support personnel |
Operative environment |
History |
Symptoms |
Hobbies (e.g. hunting etc.)/profession (risk of trauma, lead crush, EMI, special permits etc.) |
Medication (anticoagulants, antiplatelet drugs etc.) |
For replacements/revisions/upgrades: connector types, venous obstruction |
Comorbidities (diabetes → adapt insulin dose, early timing of procedure; prior chest radiotherapy,236 treatment of breast cancer,236,237 haemodialysis → contralateral implantation; dementia → measures for wound care; COPD → prudent oxygen administration due to risk of hypercapnia; presence of indwelling catheters or pacing leads, history of cardiac surgery, history of previous CIED infection, etc.) |
Evaluation of patients concerns and preferences (e.g. cosmetic aspects) |
Requirement for MRI-conditionality (including 1.5 T or 3 T conditionality) |
Allergies (antibiotics, iodine, device components e.g. silicone, titanium,238–241 etc.) |
Drug intolerance (opiates, sedatives) |
Test results |
Blood tests (haematology, INR if on VKA, renal function, electrolytes) |
ECG (underlying rhythm; LBBB → risk of traumatic heart block or requirement for CRT) |
Holter if available (sinus function, AV conduction disease) |
Exercise test if available (exercise capacity, chronotropic incompetence, atrioventricular conduction) |
View echocardiogram images if available (LVEF, chamber size, evidence of PLSVC with dilated CS, severe tricuspid regurgitation) |
Chest X-ray if available (morphological abnormalities, for comparison with post-operative X-ray) |
Other considerations |
Timing (fasting in diabetic patients, dialysis etc.) |
Required skills/experience of the operator |
Availability of required material and adequate fluoroscopy |
Availability of required support personnel |
Operative environment |
AV, atrioventricular; CIED, cardiac implantable electronic device; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CS, coronary sinus; ECG, electrocardiogram; EMI, electromagnetic interference; INR, international normalized ratio; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PLSVC, persistent left superior vena cava; VKA, vitamin K antagonist.
History |
Symptoms |
Hobbies (e.g. hunting etc.)/profession (risk of trauma, lead crush, EMI, special permits etc.) |
Medication (anticoagulants, antiplatelet drugs etc.) |
For replacements/revisions/upgrades: connector types, venous obstruction |
Comorbidities (diabetes → adapt insulin dose, early timing of procedure; prior chest radiotherapy,236 treatment of breast cancer,236,237 haemodialysis → contralateral implantation; dementia → measures for wound care; COPD → prudent oxygen administration due to risk of hypercapnia; presence of indwelling catheters or pacing leads, history of cardiac surgery, history of previous CIED infection, etc.) |
Evaluation of patients concerns and preferences (e.g. cosmetic aspects) |
Requirement for MRI-conditionality (including 1.5 T or 3 T conditionality) |
Allergies (antibiotics, iodine, device components e.g. silicone, titanium,238–241 etc.) |
Drug intolerance (opiates, sedatives) |
Test results |
Blood tests (haematology, INR if on VKA, renal function, electrolytes) |
ECG (underlying rhythm; LBBB → risk of traumatic heart block or requirement for CRT) |
Holter if available (sinus function, AV conduction disease) |
Exercise test if available (exercise capacity, chronotropic incompetence, atrioventricular conduction) |
View echocardiogram images if available (LVEF, chamber size, evidence of PLSVC with dilated CS, severe tricuspid regurgitation) |
Chest X-ray if available (morphological abnormalities, for comparison with post-operative X-ray) |
Other considerations |
Timing (fasting in diabetic patients, dialysis etc.) |
Required skills/experience of the operator |
Availability of required material and adequate fluoroscopy |
Availability of required support personnel |
Operative environment |
History |
Symptoms |
Hobbies (e.g. hunting etc.)/profession (risk of trauma, lead crush, EMI, special permits etc.) |
Medication (anticoagulants, antiplatelet drugs etc.) |
For replacements/revisions/upgrades: connector types, venous obstruction |
Comorbidities (diabetes → adapt insulin dose, early timing of procedure; prior chest radiotherapy,236 treatment of breast cancer,236,237 haemodialysis → contralateral implantation; dementia → measures for wound care; COPD → prudent oxygen administration due to risk of hypercapnia; presence of indwelling catheters or pacing leads, history of cardiac surgery, history of previous CIED infection, etc.) |
Evaluation of patients concerns and preferences (e.g. cosmetic aspects) |
Requirement for MRI-conditionality (including 1.5 T or 3 T conditionality) |
Allergies (antibiotics, iodine, device components e.g. silicone, titanium,238–241 etc.) |
Drug intolerance (opiates, sedatives) |
Test results |
Blood tests (haematology, INR if on VKA, renal function, electrolytes) |
ECG (underlying rhythm; LBBB → risk of traumatic heart block or requirement for CRT) |
Holter if available (sinus function, AV conduction disease) |
Exercise test if available (exercise capacity, chronotropic incompetence, atrioventricular conduction) |
View echocardiogram images if available (LVEF, chamber size, evidence of PLSVC with dilated CS, severe tricuspid regurgitation) |
Chest X-ray if available (morphological abnormalities, for comparison with post-operative X-ray) |
Other considerations |
Timing (fasting in diabetic patients, dialysis etc.) |
Required skills/experience of the operator |
Availability of required material and adequate fluoroscopy |
Availability of required support personnel |
Operative environment |
AV, atrioventricular; CIED, cardiac implantable electronic device; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CS, coronary sinus; ECG, electrocardiogram; EMI, electromagnetic interference; INR, international normalized ratio; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PLSVC, persistent left superior vena cava; VKA, vitamin K antagonist.
As a prerequisite for cardiac implantable electronic device (CIED) implantation the patient should be free of active infection and afebrile for >24 h. Antibiotic prophylaxis should be given in all cases (e.g. cephazolin 1–2 g or flucloxacillin 1–2 g within 1 h of incision, or, in case of allergy or high probability of resistant pathogens, vancomycin 15 mg/kg within 90–120 min). Specific measures to prevent CIED infection are covered in detail in a recent EHRA consensus document.7
Patients on anticoagulation and/or antiplatelet drugs require special considerations, as pocket haematoma increases the risk for infection.7,8 In patients with non-rheumatic atrial fibrillation (AF) and a low risk for thrombo-embolic events (CHA2DS2VASc score < 3) perioperative interruption of anticoagulation is an option.9 In all other patients, uninterrupted oral anticoagulation (aiming for international normalized ratio <3.0 or <3.5 in case of a mechanical valve prosthesis) is preferable to heparin-bridging (especially if using low molecular weight heparin), as it reduces the risk of haematoma.9–11 In the BRUISE-CONTROL 2 study,11 patients on a direct oral anticoagulant with a CHA2DS2VASc score of ≥2 had no difference in haematoma with or without interruption of therapy (doses including the morning dose were taken in the latter group). The conclusion of the study is that either management strategy is reasonable and should be based upon clinical judgement. Perioperative management of anticoagulants and/or antiplatelet drugs12 is shown in Table 3.
Dual antiplatelet therapy . | DOAC . | VKA . | OAC + antiplatelet . | |
---|---|---|---|---|
ACS at PCI or other high-risk featuresa | ||||
No | Yes | |||
<1 month Continue DAPT >1 month Continue aspirin + Discontinue P2Y12 inhibitorsb | <6months Continue DAPT (may consider discontinuing P2Y12 inhibitor if 1-6months) >6 months Discontinue P2Y12 inhibitorsb | Continue or interrupt as per operator preference and/or thromboembolic risk If interruption, then based on CrCl and specific DOAC | Continue (or consider interrupting without heparin bridging if CHA2DS2VASc<3) | Continue OAC (VKA or DOAC) Discontinue antiplatelet per patient specific risk/benefit analysis |
Dual antiplatelet therapy . | DOAC . | VKA . | OAC + antiplatelet . | |
---|---|---|---|---|
ACS at PCI or other high-risk featuresa | ||||
No | Yes | |||
<1 month Continue DAPT >1 month Continue aspirin + Discontinue P2Y12 inhibitorsb | <6months Continue DAPT (may consider discontinuing P2Y12 inhibitor if 1-6months) >6 months Discontinue P2Y12 inhibitorsb | Continue or interrupt as per operator preference and/or thromboembolic risk If interruption, then based on CrCl and specific DOAC | Continue (or consider interrupting without heparin bridging if CHA2DS2VASc<3) | Continue OAC (VKA or DOAC) Discontinue antiplatelet per patient specific risk/benefit analysis |
Prior stent thrombosis on adequate antiplatelet therapy; stenting of the last remaining patent artery; diffuse multivessel disease especially in diabetic patients; creatinine clearance <60 mL/min; ≥3 stents implanted; ≥3 lesions treated; bifurcation with 2 stents implanted; total stent length >60 mm; treatment of chronic total occlusion.
Ticagrelor ≥3 days prior surgery; Clopidogrel ≥5 days prior surgery; Prasugrel ≥7 days prior surgery. Restart as soon as possible (within 48 h).
ACS, acute coronary syndrome; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; VKA, vitamin K antagonist.
Dual antiplatelet therapy . | DOAC . | VKA . | OAC + antiplatelet . | |
---|---|---|---|---|
ACS at PCI or other high-risk featuresa | ||||
No | Yes | |||
<1 month Continue DAPT >1 month Continue aspirin + Discontinue P2Y12 inhibitorsb | <6months Continue DAPT (may consider discontinuing P2Y12 inhibitor if 1-6months) >6 months Discontinue P2Y12 inhibitorsb | Continue or interrupt as per operator preference and/or thromboembolic risk If interruption, then based on CrCl and specific DOAC | Continue (or consider interrupting without heparin bridging if CHA2DS2VASc<3) | Continue OAC (VKA or DOAC) Discontinue antiplatelet per patient specific risk/benefit analysis |
Dual antiplatelet therapy . | DOAC . | VKA . | OAC + antiplatelet . | |
---|---|---|---|---|
ACS at PCI or other high-risk featuresa | ||||
No | Yes | |||
<1 month Continue DAPT >1 month Continue aspirin + Discontinue P2Y12 inhibitorsb | <6months Continue DAPT (may consider discontinuing P2Y12 inhibitor if 1-6months) >6 months Discontinue P2Y12 inhibitorsb | Continue or interrupt as per operator preference and/or thromboembolic risk If interruption, then based on CrCl and specific DOAC | Continue (or consider interrupting without heparin bridging if CHA2DS2VASc<3) | Continue OAC (VKA or DOAC) Discontinue antiplatelet per patient specific risk/benefit analysis |
Prior stent thrombosis on adequate antiplatelet therapy; stenting of the last remaining patent artery; diffuse multivessel disease especially in diabetic patients; creatinine clearance <60 mL/min; ≥3 stents implanted; ≥3 lesions treated; bifurcation with 2 stents implanted; total stent length >60 mm; treatment of chronic total occlusion.
Ticagrelor ≥3 days prior surgery; Clopidogrel ≥5 days prior surgery; Prasugrel ≥7 days prior surgery. Restart as soon as possible (within 48 h).
ACS, acute coronary syndrome; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; VKA, vitamin K antagonist.
Operative environment
The operative room/catheterization or electrophysiology laboratory must be ventilated with >15 air changes/h (ideally 20–25 changes/h).13,14 The utility of laminar airflow on surgical site infections remains controversial.14,15 Operators should ensure that all required hardware and equipment is available before the intervention (see Table 4). Checklists and surgical ‘time-out’ are useful to avoid errors. Anaesthesia support should be readily available on the premises due to potentially life-threatening complications, to assist if necessary with analagesia or haemodynamic/respiratory support.
Required equipment and useful accessories for cardiac implantable electronic device implantation
Equipment . | Purpose . |
---|---|
Programmer (company specific) and pacing sense analyser with sterile cables | Lead testing and device programming |
Fluoroscopy with >40° viewing angles | Correct positioning of leads |
Electrocautery (optionally plasma electrocautery) | Haemostasis. Plasma electrocautery to avoid lead damage when freeing leads |
Monitoring of cardiac rhythm, cuff blood pressure and pulse oximetry, EtCO2 | Monitoring of vital signs |
Oxygen supply, suction, bag-ventilation equipment | Handling of respiratory emergencies |
Emergency cart with drugs and intubation material (rapidly available on site) | Management of cardiovascular and rhythm emergencies |
External defibrillator (preferably biphasic) capable of providing temporary transcutaneous pacing (placed in an antero-posterior position) | Cardioversion/defibrillation, temporary transcutaneous pacing |
Echocardiography (available rapidly on site) | Confirmation of tamponade |
Accessories | |
Long sheaths (7–9 F) e.g. 23 cm | Placement of leads across vein stenoses |
Hydrophilic 0.035″ guidewire | Crossing of vein stenoses and tortuous vessels |
Extra-stiff 0.035″ guidewire | Provide support to place introducer sheaths across stenotic or tortuous vessels |
Lead stylets (e.g. 65 cm) | Backup in case of kinking of stylets provided with the lead |
Tunnelization tools (e.g. trocar, chest tube etc) | Allows contralateral implantation with tunnelization to pocket in case of vein occlusion in upgrades/revisions |
Non-dynamometric wrench (Allen key) | Freeing of frozen setscrews |
Lead insulation repair kit (silicone sleeves, glue) | Repair of insulation breach identified at generator change/lead revision |
Lead splicing adaptor (e.g. Medtronic 5866–9 M) | Salvage of fractured pacing lead |
Lead caps | Capping of abandoned leads |
Connector plug (IS-1, DF-1) | Plugging unused generator ports |
Lead extenders | Tunneling to contralateral pocket |
Sterile lubricant, pure alcohol | Freeing of frozen leads at generator change |
Pericardial puncture tray assembling all required accessories (available in the room) | Emergent pericardiocentesis |
Equipment . | Purpose . |
---|---|
Programmer (company specific) and pacing sense analyser with sterile cables | Lead testing and device programming |
Fluoroscopy with >40° viewing angles | Correct positioning of leads |
Electrocautery (optionally plasma electrocautery) | Haemostasis. Plasma electrocautery to avoid lead damage when freeing leads |
Monitoring of cardiac rhythm, cuff blood pressure and pulse oximetry, EtCO2 | Monitoring of vital signs |
Oxygen supply, suction, bag-ventilation equipment | Handling of respiratory emergencies |
Emergency cart with drugs and intubation material (rapidly available on site) | Management of cardiovascular and rhythm emergencies |
External defibrillator (preferably biphasic) capable of providing temporary transcutaneous pacing (placed in an antero-posterior position) | Cardioversion/defibrillation, temporary transcutaneous pacing |
Echocardiography (available rapidly on site) | Confirmation of tamponade |
Accessories | |
Long sheaths (7–9 F) e.g. 23 cm | Placement of leads across vein stenoses |
Hydrophilic 0.035″ guidewire | Crossing of vein stenoses and tortuous vessels |
Extra-stiff 0.035″ guidewire | Provide support to place introducer sheaths across stenotic or tortuous vessels |
Lead stylets (e.g. 65 cm) | Backup in case of kinking of stylets provided with the lead |
Tunnelization tools (e.g. trocar, chest tube etc) | Allows contralateral implantation with tunnelization to pocket in case of vein occlusion in upgrades/revisions |
Non-dynamometric wrench (Allen key) | Freeing of frozen setscrews |
Lead insulation repair kit (silicone sleeves, glue) | Repair of insulation breach identified at generator change/lead revision |
Lead splicing adaptor (e.g. Medtronic 5866–9 M) | Salvage of fractured pacing lead |
Lead caps | Capping of abandoned leads |
Connector plug (IS-1, DF-1) | Plugging unused generator ports |
Lead extenders | Tunneling to contralateral pocket |
Sterile lubricant, pure alcohol | Freeing of frozen leads at generator change |
Pericardial puncture tray assembling all required accessories (available in the room) | Emergent pericardiocentesis |
Required equipment and useful accessories for cardiac implantable electronic device implantation
Equipment . | Purpose . |
---|---|
Programmer (company specific) and pacing sense analyser with sterile cables | Lead testing and device programming |
Fluoroscopy with >40° viewing angles | Correct positioning of leads |
Electrocautery (optionally plasma electrocautery) | Haemostasis. Plasma electrocautery to avoid lead damage when freeing leads |
Monitoring of cardiac rhythm, cuff blood pressure and pulse oximetry, EtCO2 | Monitoring of vital signs |
Oxygen supply, suction, bag-ventilation equipment | Handling of respiratory emergencies |
Emergency cart with drugs and intubation material (rapidly available on site) | Management of cardiovascular and rhythm emergencies |
External defibrillator (preferably biphasic) capable of providing temporary transcutaneous pacing (placed in an antero-posterior position) | Cardioversion/defibrillation, temporary transcutaneous pacing |
Echocardiography (available rapidly on site) | Confirmation of tamponade |
Accessories | |
Long sheaths (7–9 F) e.g. 23 cm | Placement of leads across vein stenoses |
Hydrophilic 0.035″ guidewire | Crossing of vein stenoses and tortuous vessels |
Extra-stiff 0.035″ guidewire | Provide support to place introducer sheaths across stenotic or tortuous vessels |
Lead stylets (e.g. 65 cm) | Backup in case of kinking of stylets provided with the lead |
Tunnelization tools (e.g. trocar, chest tube etc) | Allows contralateral implantation with tunnelization to pocket in case of vein occlusion in upgrades/revisions |
Non-dynamometric wrench (Allen key) | Freeing of frozen setscrews |
Lead insulation repair kit (silicone sleeves, glue) | Repair of insulation breach identified at generator change/lead revision |
Lead splicing adaptor (e.g. Medtronic 5866–9 M) | Salvage of fractured pacing lead |
Lead caps | Capping of abandoned leads |
Connector plug (IS-1, DF-1) | Plugging unused generator ports |
Lead extenders | Tunneling to contralateral pocket |
Sterile lubricant, pure alcohol | Freeing of frozen leads at generator change |
Pericardial puncture tray assembling all required accessories (available in the room) | Emergent pericardiocentesis |
Equipment . | Purpose . |
---|---|
Programmer (company specific) and pacing sense analyser with sterile cables | Lead testing and device programming |
Fluoroscopy with >40° viewing angles | Correct positioning of leads |
Electrocautery (optionally plasma electrocautery) | Haemostasis. Plasma electrocautery to avoid lead damage when freeing leads |
Monitoring of cardiac rhythm, cuff blood pressure and pulse oximetry, EtCO2 | Monitoring of vital signs |
Oxygen supply, suction, bag-ventilation equipment | Handling of respiratory emergencies |
Emergency cart with drugs and intubation material (rapidly available on site) | Management of cardiovascular and rhythm emergencies |
External defibrillator (preferably biphasic) capable of providing temporary transcutaneous pacing (placed in an antero-posterior position) | Cardioversion/defibrillation, temporary transcutaneous pacing |
Echocardiography (available rapidly on site) | Confirmation of tamponade |
Accessories | |
Long sheaths (7–9 F) e.g. 23 cm | Placement of leads across vein stenoses |
Hydrophilic 0.035″ guidewire | Crossing of vein stenoses and tortuous vessels |
Extra-stiff 0.035″ guidewire | Provide support to place introducer sheaths across stenotic or tortuous vessels |
Lead stylets (e.g. 65 cm) | Backup in case of kinking of stylets provided with the lead |
Tunnelization tools (e.g. trocar, chest tube etc) | Allows contralateral implantation with tunnelization to pocket in case of vein occlusion in upgrades/revisions |
Non-dynamometric wrench (Allen key) | Freeing of frozen setscrews |
Lead insulation repair kit (silicone sleeves, glue) | Repair of insulation breach identified at generator change/lead revision |
Lead splicing adaptor (e.g. Medtronic 5866–9 M) | Salvage of fractured pacing lead |
Lead caps | Capping of abandoned leads |
Connector plug (IS-1, DF-1) | Plugging unused generator ports |
Lead extenders | Tunneling to contralateral pocket |
Sterile lubricant, pure alcohol | Freeing of frozen leads at generator change |
Pericardial puncture tray assembling all required accessories (available in the room) | Emergent pericardiocentesis |
Staff, training, and qualifications
Team members should be proficient with sterile techniques and practice. Poor adherence to these standards results in higher rates of surgical site infections.16 The operator should have EHRA level 2 or national certification, equivalent expertise, or be adequately supervised if in training. Procedural volume is also important to maintain expertise; operators or centres with <50 implantations/year have been shown to have higher complication rates.17,18
In addition to the operator, at least one non-scrubbed nurse or allied professional proficient with supporting device implantation and procedural sedation should be present in the room, but the presence of unnecessary personnel should be avoided. All personnel should be trained with radioprotection and the operator should strive to minimize radiation exposure.19–21 The operator, or another physician present on site, should be able to perform emergency pericardiocentesis and cardiopulmonary resuscitation manoeuvres.
Specific operative steps
A checklist covering the different operative steps is provided in the Supplementary material online, Appendix, as are links to online video tutorials, which provide practical tips on performing selected techniques. Measures to prevent infection have been recently covered in a consensus document7 and will not be repeated here. Surgical hand preparation with antimicrobial soap and water or alcohol-based hand rubs should be performed according to the World Health Organization global guidelines for prevention of surgical site infection (see Supplementary material online, Appendix).14
Left-sided implants are usually favoured due to this being the non-dominant side [and also due to lower defibrillation thresholds (DFT) for ICDs]. The decision should be individualized and account for specific requirements (see Table 2).
Incision and pocket creation
After prepping the skin, local anaesthesia is mostly performed using 1% lidocaine (maximum dose 4.5 mg/kg or 300 mg) which may also be used semi-diluted to administer a larger volume over a greater area,22 or mixed with a long-acting local anaesthetic e.g. bupivacaine 0.25% or ropivacaine 0.5%. The use of epinephrine-containing local anaesthetics has been associated with a higher incidence of haematomas and should be avoided.23 Deep sedation or general anaesthesia may be required in agitated patients, or in specific instances (e.g. lead tunnelization or submuscular pockets). A horizontal incision inferior and parallel to the clavicle, or an oblique incision slightly medial or along the deltopectoral groove may be performed according to operator preference, and have shown to yield similar scar healing (see Supplementary material online, Video S1).24 The oblique incision may provide better access for cephalic vein cutdown, but being relatively lateral, the pocket should be prepared more medially with enough spacing to avoid conflict with the shoulder.
Many operators prefer to create the pocket at the beginning of the procedure for new implants, as local anaesthesia may be more effective at this stage, and bleeding can be monitored during the intervention. It is important to perform dissection down to the subfascial plane, even when a generous amount of adipose tissue is present (see Supplementary material online, Video S2). With the relatively small size of current generators, the majority of operators chose to implant PMs and ICDs in a subcutaneous (subfascial prepectoral) pocket. A submuscular pocket may be considered in thin patients who are at risk for pocket erosion, for cosmetic reasons, or in case of Twiddler’s syndrome. It is important to respect anatomical planes (i.e. between the pectoralis major and minor muscles) and not to create an intramuscular pocket to avoid undue tissue damage and bleeding (see Supplementary material online, Video S3). Submammary25,26 and axillary27 pockets have also been performed for cosmetic reasons but are rarely used.
Venous access
Due to variations in patient anatomy and for the reasons outlined below, implanters should be proficient with cephalic venous cutdown, axillary and subclavian vein puncture. It is useful to place an ipsilateral intravenous line in case a venogram is required; this does not increase the risk of infection.28 The use of micropuncture kits allows vascular access with a small 21 gauge needle as opposed to the standard method, which requires an 18 gauge needle and can be used to decrease severity of complications due to inadvertent arterial or pleural puncture.
Cephalic venous cutdown
The cephalic vein is the first approach in 60% of centres according to the EHRA survey.6 After distal ligation, the vein may be incised followed by direct introduction of the lead (see Figure 1) or a puncture may be performed with introduction of a sheath (see Supplementary material online, Video S4). In case of difficulty inserting the lead or if more than one lead is implanted, using a guidewire and introducer sheath is helpful.

Cephalic venous cutdown (right-sided). (A) Dissection to the deltopectoral groove, with exposure of the cephalic vein to which are looped a proximal (top) and distal tie (bottom). The distal tie is fastened and gently pulled with a clamp. The anterior part of the vein is lifted by forceps and a venotomy made with a scalpel or scissors to expose the lumen of the vein (a common mistake is to incise only to the adventitia). Alternatively, the vein may be punctured with a needle or venous catheter to introduce a guidewire. (B) The vein lifter (yellow tool) is used to introduce the lead (alternatively a guidewire can be inserted to use a sheath). If blood prevents visualization of the lumen, the proximal tie can be pulled gently to prevent backflow and then released once the lead is inserted.
Cephalic vein access has the advantage of avoiding pneumothorax and reducing the risk of lead dysfunction compared to subclavian puncture [odds ratio (OR) 0.25, 95% confidence interval (CI) 0.13–0.51, P < 0.001].29 Successful cannulation is reported in approximately 60–80% of patients,30–33 but may reach >90% with the help of hydrophilic guidewires or use of retro-pectoral veins.34–36 Hydrophilic angulated guidewires are useful for crossing venous valves and to steer access towards the subclavian vein when the lead tracks towards the arm (asking the patient to lift the shoulder while steering the lead or wire can also help). Introduction of up to three leads using introducer sheaths is possible in the great majority of patients, but in rare instances, a separate puncture for venous access is required.36 Bleeding complications are not significantly different compared to subclavian access.29,37 Supra-clavicular course of the vein is a rare variant that should be recognized by fluoroscopy and by palpating the lead over the clavicle.38,39 In this rare instance, alternative routes should be used to avoid discomfort or lead complications.
Intra-thoracic subclavian vein puncture
Subclavian puncture was initially popular due to its high success rate (approximately 95%32,40,41) but carries a risk of pneumothorax (approximately 1–2% of patients40,42,43) and lead failure due to subclavian crush (see Figure 2).29,32,44–46 Friction with the clavicle, subclavius muscle or costo-clavicular ligament may also restrict lead manipulation and positioning. Subclavian access has been associated with a higher risk of bleeding complications in patients receiving antiplatelet drugs.47 Other rare complications include arterio-venous fistula,48 transient phrenic nerve palsy due to local anaesthesia,49 and thoracic duct injury. For these reasons, it is recommended that intrathoracic subclavian vein puncture is not used as a first-line approach, but as a bailout technique in case other routes have failed, or for venous access medial to occlusions.50 The puncture should be as lateral as possible to avoid lead crush (see Supplementary material online, Video S5). It may be performed using only bony landmarks (below and slightly lateral to the most prominent part of the clavicle for the puncture site, directing the needle towards the sternal notch) or under fluoroscopy aiming towards the middle of the clavicular head. A venogram may be useful to target the vein and reduce the risk of complications. For dual-chamber devices, separate punctures may reduce the risk of bleeding and of lead dysfunction due to crowding, but this has not been proven and may expose the patient to increased risk of pneumothorax compared to a single puncture, especially in case of difficult access or risky anatomy [e.g. low body mass index (BMI) or chronic obstructive pulmonary disease].

Lead crush with subclavian vein puncture. Patient with a single chamber pacemaker who had lead failure due to subclavian crush (arrow). An additional lead was implanted by axillary vein puncture.
Extra-thoracic subclavian and axillary vein puncture
The axillary vein becomes the extra-thoracic subclavian vein as it crosses over the inferior border of the first rib. These segments are considered analogous for the purposes of this document. Axillary vein puncture is being increasingly adopted following the introduction of new techniques which have improved its safety and efficacy, as well as evidence of superior success rates compared to cephalic venous cutdown30,32,33 and improved outcome compared to subclavian vein puncture, especially with regard to reducing the risk of lead failure.32,40,46 The risk of bleeding is not different compared to cephalic access.37
A variety of techniques have been described using anatomic landmarks,51–53 a venogram,30,32,54,55 a guidewire from the antecubital vein as a roadmap,55 fluoroscopic bony landmarks (most often the outer border of the first rib)31,33,54,56–58 or ultrasound,41,59–64 with approximately 95% success. A useful technique is to access the axillary vein using a 35° caudal fluoroscopic view and to aim the region overlying the outer border of the first rib (see Figure 3 and Supplementary material online, Video S6), which has been shown to be successful in 96% of cases.58 This exposes the subclavian space and the anterior outline of the lungs, thereby eliminating the risk of pneumothorax if the technique is properly performed. The same view may be used with a venogram if the vein is not accessed using fluoroscopic landmarks only. A shallow approach using this technique also reduces X-ray exposure to the hands as well as flexion stress on the lead (which may be an issue with a steep angle for ‘walking’ the puncture needle on the first rib).

Axillary vein puncture using fluoroscopic landmarks. The caudal tilt exposes the outer margin of the lung, allowing safe puncture and minimizing risk of pneumothorax. The target site is shown in the rectangle (top right). After successful puncture, a guidewire is inserted and the needle entry site in the vein can be appreciated (bottom right).
Ultrasonography is likely to be increasingly adopted as it reduces X-ray exposure to the operator (see Supplementary material online, Video S7), has a self-learned success rate of 97.7%,65 and its intra-operative use is facilitated by the advent of wireless devices.60 It also allows to concomitantly perform pectoral nerve block.66
In some cases, narrowing of the axillary vein may occur due to compression by haematoma induced by inadvertent arterial puncture or bleeding from the muscle.
Troubleshooting venous access
In patients previously implanted with leads, venous stenosis of >75% is found in 6–21% of patients and vein occlusion in 6–26%.67–69 Superficial collateral veins may be visible on the patient’s chest, but do not necessarily indicate obstruction,70 and most patients have no complaints. In patients requiring an upgrade, it is very useful to perform a venogram prior to skin incision to confirm patency using the same view as for venous access (e.g. 35°caudal tilt) to plan the procedure. Peripheral venography may however overestimate occlusion with collaterals, as more selective dye injection via a dilator can reveal flow through the lesion in approximately two-thirds of these cases.71 Hydrophilic 0.035″ guidewires, hydrophilic catheters, and long sheaths are very useful to cross stenoses. Hydrophilic wires should be handled carefully to avoid perforation. More medial punctures50,72,73 or venoplasty69,71,74 may be performed for occlusions. For upgrades, contralateral venous access with subcutaneous tunnelization to the pocket may be performed, e.g. with a trochar and a chest tube.75 Other more invasive options are lead extraction and the ‘inside out’ technique76 which need to be performed in specialized centres.
In patients with pre-existing leads which are to be abandoned or explanted, the retained wire under lead insulation technique can be used to gain venous access if the old lead is able to be pushed a few centimetres into the vein.77
Alternative routes for venous access as a bailout solution include the internal/external jugular vein,78 and iliofemoral access.79,80 Leadless PMs, subcutaneous ICDs, or epicardial leads are options which should be considered in case of venous access issues. Lead extraction may also be an option to gain venous access (either using extraction sheaths via a superior approach, or a femoral approach with a retained guidewire in the lead lumen).
The azygous vein may be unintentionally cannulated by the guidewire or the lead. This can be recognized by the posterior course of the vein just above the right main bronchus (Figure 4).

Unintentional cannulation of the azygous vein by the J-wire, with the pacing lead in the superior vena cava/right atrium for comparison. Note the course of the J-wire above the right main bronchus shown by the dotted lines in the postero-anteior (PA) view, which plunges posteriorly in the left anterior oblique (LAO) view.
A persistent left superior vena cava (PLSVC) is encountered in up to 0.5% of patients.81 This structure usually regresses to become the Marshall vein/ligament, and drains into the coronary sinus. Ventricular lead placement can be challenging but can be facilitated by shaping the stylet with a large J curve (Figure 5). It is useful to search for an innominate vein which is sometimes present (but may be small) and can facilitate implantation from the usual route. Right-sided implant may be necessary, but a right superior vena cava may be absent in a minority of cases. Right sided venography is advisable to check for presence of a right-sided superior vena cava, before attempting to switch sides, should a PLSVC be identified.

Persistent left superior vena cava. (A) Single left superior vena cava (absent right superior vena cava) draining into a severely dilated coronary sinus. (B) Persistent left superior vena cava in a patient with a coexistent right vena cava (without a bridging innominate vein) and smaller size of the coronary sinus. (C) Same patient as A with a dual chamber pacemaker (PA view). Note the lead course leftward of the spine, and the alpha loop of the right ventricular lead. (D) Same patient as A (left lateral view). Note the posterior course of both leads within the coronary sinus.
Right ventricular lead placement
The ventricular lead is usually placed before the atrial lead (unless AAI pacing is considered) in order to provide backup pacing and to avoid dislodgment. Anatomic sites for right ventricular pacing are shown in Figure 6. According to the 2013 EHRA survey,6 half of the centres declared the right ventricular apex (RVA) as their preferred lead position, followed by the interventricular septum and the outflow tract in 47% and 3% of centres, respectively. A manually curved stylet is often used to cross the tricuspid valve (it is also possible to prolapse the lead off the right atrial wall into the ventricle by manipulating the stylet). Inadvertent cannulation of the coronary sinus or its branches is suggested by ‘tracking’ of the lead and absence of ventricular premature beats, and can be confirmed in the left anterior oblique (LAO) view.

Anatomy of the heart chambers relevant for pacing. (Left) Right anterior oblique view (∼20°) of the heart. Note proximity of the tip (*) of the right atrial appendage (RAA) to the aortic root (Ao) and the right ventricle. The target site for right atrial lead implantation is shaded (grey circle). (Middle) Right anterior oblique view (∼20°) of the heart after dissection of the anterior wall of the right heart chambers. The pacing lead is positioned on the mid-septum against the septo-marginal trabeculation (SMT) below the supraventricular crest (SVcrest), which forms the inferior border of the right ventricular outflow tract (RVOT). A noticeable «jump» can be seen as the lead is pulled back from the RVOT over these structures. (Right) Right anterior oblique view (∼30°) of the dissected transilluminated heart. Note how thin the right atrial appendage (RAA) wall is between pectinate muscles. The tricuspid valve leaflets have been excised to expose the membranous septum (MS), and their hinge points are represented by the dotted line. Approximate location of the atrioventricular node (AVN) and course of the His bundle and right bundle branch (RBB) are shown. Other abbreviations: BB, Bachmann’s bundle region; CS, coronary sinus; FO, fossa ovalis; PA, pulmonary artery; RVA, right ventricular apex; SVC, superior vena cava; TV, anterior leaflet of tricuspid valve. Images courtesy of Maxim Didenko, MD, PhD.
Right ventricular apex
Leads have traditionally been placed at the RVA due to ease of positioning and presence of trabeculae for anchoring passive leads. Concern has arisen, however, regarding long-term deleterious effects of RVA pacing on left ventricular function, heart failure and death.82,83 In addition, it has been shown that perforation is independently associated with an RVA position for active-fixation leads (OR 3.37, 95% CI 1.17–9.67, P = 0.024).84
As a general rule, with extendible helix leads, fluoroscopic markers should be used for confirming deployment (and not number of turns). Over-rotation may result in lead destabilization, perforation, or damage to the lead. This writing group recommends a number of practical precautions to avoid complications when implanting any type of lead (see Table 5).
Do . | Don’t . |
---|---|
Manipulate lead/stylet carefully Withdraw the stylet by 1–2 cm when advancing the lead up against the ventricular free walla Check lead position in the RAO 30° and LAO 40–60°views Deploy the screw while maintaining the exposed part of the lead straight to avoid torque buildup and sudden extension of the helixb Check the fluoroscopic markers for helix extensionb Check for current of injuryb Test for extracardiac stimulationa Verify stability of the lead by pushing the lead with the stylet retracted by 5–6 cm Leave adequate slack (and check with deep inspiration) Check sensing amplitude after having adjusted lead slack Clean the connector pin before inserting into the generator | Manipulate stylet with bloody gloves (⇒clogging of lead lumen) Apply excessive wall contact with a fully deployed stylet in the leada Over-rotate when fixating (will result in rotation of the entire lead body, with reduced stability and increased risk of perforation)b Base helix deployment on the number of rotations (variable with lead course)b Let the pinch-on tool spin back after fixationb (will partially unscrew helix) Pull on the lead for verifying stability |
Do . | Don’t . |
---|---|
Manipulate lead/stylet carefully Withdraw the stylet by 1–2 cm when advancing the lead up against the ventricular free walla Check lead position in the RAO 30° and LAO 40–60°views Deploy the screw while maintaining the exposed part of the lead straight to avoid torque buildup and sudden extension of the helixb Check the fluoroscopic markers for helix extensionb Check for current of injuryb Test for extracardiac stimulationa Verify stability of the lead by pushing the lead with the stylet retracted by 5–6 cm Leave adequate slack (and check with deep inspiration) Check sensing amplitude after having adjusted lead slack Clean the connector pin before inserting into the generator | Manipulate stylet with bloody gloves (⇒clogging of lead lumen) Apply excessive wall contact with a fully deployed stylet in the leada Over-rotate when fixating (will result in rotation of the entire lead body, with reduced stability and increased risk of perforation)b Base helix deployment on the number of rotations (variable with lead course)b Let the pinch-on tool spin back after fixationb (will partially unscrew helix) Pull on the lead for verifying stability |
At the right ventricular apex.
With an active-fixation lead.
LAO, left anterior oblique; RAO, right anterior oblique.
Do . | Don’t . |
---|---|
Manipulate lead/stylet carefully Withdraw the stylet by 1–2 cm when advancing the lead up against the ventricular free walla Check lead position in the RAO 30° and LAO 40–60°views Deploy the screw while maintaining the exposed part of the lead straight to avoid torque buildup and sudden extension of the helixb Check the fluoroscopic markers for helix extensionb Check for current of injuryb Test for extracardiac stimulationa Verify stability of the lead by pushing the lead with the stylet retracted by 5–6 cm Leave adequate slack (and check with deep inspiration) Check sensing amplitude after having adjusted lead slack Clean the connector pin before inserting into the generator | Manipulate stylet with bloody gloves (⇒clogging of lead lumen) Apply excessive wall contact with a fully deployed stylet in the leada Over-rotate when fixating (will result in rotation of the entire lead body, with reduced stability and increased risk of perforation)b Base helix deployment on the number of rotations (variable with lead course)b Let the pinch-on tool spin back after fixationb (will partially unscrew helix) Pull on the lead for verifying stability |
Do . | Don’t . |
---|---|
Manipulate lead/stylet carefully Withdraw the stylet by 1–2 cm when advancing the lead up against the ventricular free walla Check lead position in the RAO 30° and LAO 40–60°views Deploy the screw while maintaining the exposed part of the lead straight to avoid torque buildup and sudden extension of the helixb Check the fluoroscopic markers for helix extensionb Check for current of injuryb Test for extracardiac stimulationa Verify stability of the lead by pushing the lead with the stylet retracted by 5–6 cm Leave adequate slack (and check with deep inspiration) Check sensing amplitude after having adjusted lead slack Clean the connector pin before inserting into the generator | Manipulate stylet with bloody gloves (⇒clogging of lead lumen) Apply excessive wall contact with a fully deployed stylet in the leada Over-rotate when fixating (will result in rotation of the entire lead body, with reduced stability and increased risk of perforation)b Base helix deployment on the number of rotations (variable with lead course)b Let the pinch-on tool spin back after fixationb (will partially unscrew helix) Pull on the lead for verifying stability |
At the right ventricular apex.
With an active-fixation lead.
LAO, left anterior oblique; RAO, right anterior oblique.
The lead may be positioned slightly proximal to the apex so as to point in a slightly inferior orientation. The right anterior oblique (RAO) 30° view is useful to expose the long axis of the heart and better outline the apex (see Figure 7). The LAO 40–60° view should also be checked to ensure that the lead is not inadvertently placed in a coronary sinus tributary or in the left ventricle via a septal defect (or arterial puncture), as this can be missed in the postero-anterior view.85,86

Lead position in the right ventricular apex. Note how the apical position is more apparent in the right anterior oblique (RAO) 30° view than in the postero-anterior (PA) view. The left anterior oblique (LAO) view allows to rule out placement of the lead in the left ventricle via a septal defect or in a tributary of the coronary sinus (e.g. in a posterior vein). Images modified from a virtual reality simulator used for training device implantation, with anatomy reconstructed from patient CT scans.
Lead stability should be checked by withdrawing the stylet to the level of the inlet and buckling the lead by pushing it. Sufficient slack should be left to form a ‘heel’. Temporary pacing at maximum output should be performed while palpating or observing under fluoroscopy the left hemi-diaphragm to rule out phrenic capture. Implantation technique is shown in Supplementary material online, Video S8.
Right ventricular septum
The right ventricular septum (RVS) has been advocated as a more physiological alternative to the RVA to reduce adverse effects of pacing-induced dyssynchrony, with equivocal results.82,83 Right ventricular systolic function87 and tricuspid regurgitation87,88 are also similar to apical pacing. Nevertheless, an advantage is that perforation may be avoided. Electrical parameters are comparable to apical pacing.89,90
A caveat is that many reports have shown that leads intended for the RVS are often positioned on the anterior free wall or antero-septal groove (which forms a natural recess into which the lead wedges).91–95 This site may possibly result in left ventricular dysfunction,92,93 perforation,89 and in rare instances in myocardial infarction, due to the lead being screwed into the left anterior descending artery.96–98 It is therefore important to target a true septal position.
Studies which have validated final lead position by computed tomography (CT) or echocardiography have demonstrated that the LAO view alone is insufficient to confirm septal pacing and that an RAO view to visualize the long axis of the heart is also necessary.91,94,95 Likewise, the angle of orientation of the lead in the LAO view is not indicative of a septal location,95,99 as it may simply be modified by adjusting lead slack.100 Furthermore, the LAO 40° may not adequately visualize the heart in its short axis, which is often better represented by the LAO 60° view.101
A fluoroscopic landmark which can be used for positioning septal leads is shown in Figure 8.91

Fluoroscopic landmarks for right ventricular mid-septal lead positioning. The lead is implanted in the antero-septal groove and masquerades as a septal position in the left anterior oblique (LAO) 40–60° and postero-anterior (PA) views. The Right anterior oblique (RAO) 20–30°view shows that the lead is in fact anterior. A 3 × 3 grid can be drawn from the lateral border of the spinal column to the apex in the RAO 20–30°view, targeting the middle square.91 Dilatation or hypertrophy of the left ventricle may however modify the cardiac silhouette and the landmark. Images modified from Burri et al.91
Ventriculography in the RAO 20–30° view can accurately depict the contour of the right ventricle in its long axis for precise targeting of the RVS.99 Although this may not be practical to perform on a routine basis, it may be useful in patients with dilated or hypertrophied ventricles, which can alter the cardiac silhouette. One should also evaluate lead tip movement, which is more ample with fixation to the free wall compared to the RVS.
A number of electrocardiographic (ECG) criteria for confirming lead position have been proposed, but are limited by improper validation of the pacing site,102,103 or lack of comparison to anteroseptal/anterior free wall pacing.104 All studies which have used echocardiography,105 CT scans,94,95 or electro-anatomical mapping106 for validating pacing sites have shown that ECG criteria are unreliable indicators of RVS pacing.
The lead may slide on the RVS using a two-dimensional curved stylet. In order to facilitate positioning the lead, a posterior distal bend can be made (see Figure 9) to shape a three-dimensional (3D) stylet as initially described by Mond et al.91,107

Shaping of stylets for ventricular lead positioning. (A) Shaping of a 2D stylet. Use of the barrel of a 10 mL syringe (smaller syringes may also be used) for entering the right ventricle (apical or septal positioning). (B1–4) Shaping of a 3D stylet. Use of a 5 mL syringe to shape a distal sharp posterior curve, followed by a larger proximal curve using a 10 mL syringe (the nozzle of this syringe may also be used for the distal curve). The stylets may also be shaped using a metalic tool with a compress or the fingers. Reproduced from Burri et al.91
Positioning may either be done using the ‘pullback’ technique from the pulmonary artery (see Supplementary material online, Video S9) or directly on the RVS. By combining the 3D stylet and the fluoroscopic landmarks described above in the RAO 30° and LAO 40–60° views, around 95% of the leads can be correctly placed on the RVS.91,94 The target area is the septomarginal trabeculation/moderator band (see Figure 6), which form a natural buttress to stabilize the lead and also harbours the right bundle branch108 and may also help preserve electrical synchrony.
Only active fixation leads should be used for RVS pacing as this allows positioning in smooth-walled regions. If the lead is not stable, it will usually drop with stylet withdrawal. It is important to adjust lead slack to avoid rocking of the lead tip, which may result in dislodgement (as will too little slack, see Supplementary material online, Video S9).
Right ventricular outflow tract pacing
The same stylet shape and fluoroscopic views (RAO/LAO) can be used for implanting leads on the right ventricular outflow tract (RVOT) septum as for the RVS. This may however be more challenging, with heterogeneous lead positions,109–111 due to the smaller target area of this funnel-shaped structure. Furthermore, the RVOT septum is free-standing, except for its inferior part, i.e. without direct contact with the interventricular septum,112 and it is thin-walled, tapering from 3–5 mm down to 1–2 mm in its subvalvular segment,108 raising concern for perforation. There is little evidence that this pacing site is beneficial, although long-term lead performance has been shown to be satisfactory.113,114
Right atrial lead placement
Right atrial leads with dual-chamber devices have been consistently associated with a 1.5–2× increased risk of complications compared to single chamber VVI-systems.17,115–120 The main issues are lead dislodgement and perforation.121 Unless the patient has a VDD system (and does not require atrial pacing), an atrial lead is necessary to maintain atrioventricular synchrony and to confirm atrial arrhythmias. An atrial lead also greatly facilitates follow-up of arrhythmic episodes with ICDs, and tended to reduce inappropriate shocks in a meta-analysis of six trials randomizing single- vs. dual-chamber ICDs (OR 1.46, 95% CI 0.97–2.19; P = 0.07), without, however, impacting mortality.122
Right atrial appendage
The right atrial appendage (RAA) comprises the entire trabeculated anterolateral triangular part of the right atrium. It is demarcated posteriorly by the crista terminalis, which separates it from the smooth-walled vestibule. Wall thickness is 1–2 mm, with the lateral appendage being particularly thin (see Figure 6); histology shows one or few myocytes thickness between pectinate muscles with some areas being devoid of myocardium.123,124 One should therefore avoid placing leads on the lateral wall of the RAA and right atrium to avoid perforation, which may result in tamponade, or in rare instances, right-sided pneumothorax and pneumopericardium.125–128 The tip of the RAA points leftwards to lie over the aortic root,129 which can result in life-threatening laceration of the aorta by active-fixation leads.124,130–133 It is therefore probably advisable to place the right atrial lead in the anterior RAA (see Figure 6).
Patients may complain of parasternal pain during implantation, which may indicate perforation despite normal electrical parameters (and is confirmed if the pain disappears after repositioning the lead). Passive J-shaped leads have been shown to have a lower risk of pericardial complications than active leads,121,134 but may be slightly more prone to dislodgment.134–136 Active J-shaped leads do not confer any major advantage compared to straight leads.137,138
The medial RAA is also in proximity to the RVOT,124 which can result in far-field R-wave (FFRW) oversensing. This can lead to inappropriate mode switching in >20% of patients,139 to proarrhythmia with atrial antitachycardia pacing,140 or issues with ICD rhythm discrimination algorithms. FFRW amplitude should therefore be carefully assessed at implantation (ideally before deploying the helix as it is not affected by fixation) and should be <20% compared to the near-field atrial electrogram. This is best accomplished by direct visualization of the intracardiac electrogram, rather than relying solely on a digital reading of the P-wave amplitude. FFRW amplitude can be reduced by placing the lead in the anterior RAA (pointing towards the operator in a postero-anterior view—see Supplementary material online, Video S10). It is useful to check lead position in the RAO/LAO views, as the ‘windscreen wiper’ movement may be more visible than in the postero-anterior projection. After fixating the lead, stability should be verified by withdrawing the stylet to the superior vena cava and pushing the lead. Sufficient slack should be left to prevent straightening of the lead, as this may result in suboptimal electrical parameters. It should be borne in mind that the amount of lead slack can significantly change near- and far-field sensing amplitude due to changes in atrial dipole orientation with respect to the activation vector (both in the frontal and horizontal planes).
Alternative pacing sites
In an attempt to reduce AF, alternative pacing sites have been studied. These include Bachmann’s bundle, the coronary sinus ostium area, and even dual site atrial pacing. Meta-analyses have failed to show any advantage of progression to persistent/permanent AF or lead-related complications compared to RAA pacing.141,142 The interatrial septum may avoid perforation of the free wall, but proximity to the aortic root with risk of perforation should be borne in mind.131 Due to these considerations and the added complexity of lead placement, this writing group does not recommend atrial septal pacing as a first-line approach. It may however be useful as an option in case of issues with RAA lead placement (e.g. scarring after cannulation for cardiac surgery).
Electrical testing
Acute capture thresholds should be ≤1.5 [email protected] ms, with sensing amplitudes ≥1.5 mV for the atrium and ≥4mV for the ventricle, and lead impedances should be within normal specified limits (usually 400–1200 Ohms). It is important to not simply record measurements, but to observe waveforms (e.g. presence of FFRW on atrial leads, as mentioned above). A negative electrogram can result from reversal of the crocodile clips on the lead143 (with elevated capture thresholds) or may indicate lead perforation.144 With active-fixation leads it is important to confirm presence of current of injury (COI) (see Figure 10).

Recordings from the pacing system analyser at implantation. Increase in current of injury before (left) and after (right) helix deployment. Top: atrial (A) lead (note absence of a far-field R-wave). Bottom: Ventricular (V) lead.
Some degree of ST elevation on the intracardiac electrogram can be encountered even before helix deployment, simply due to contact with the myocardium. To indicate adequate fixation, the elevation should increase compared to baseline and be clearly visible.145–148 Capture thresholds can be high immediately after fixation with a COI, but usually decrease over the following minutes (making it worthwhile to recheck thresholds rather than immediately repositioning the lead). Sensing may also be affected by COI and should be rechecked. The significance of slew rate for adequate lead fixation is uncertain.
Electrical testing is usually straightforward for ventricular leads but may be challenging for atrial leads (see practical tips in the Supplementary material online, Appendix).
Lead and generator fixation
Haemostatic sutures using resorbable braided sutures around lead insertion sites are useful to control bleeding. However, care should be taken not to tie directly to the lead body as this may damage the insulation (see Supplementary material online, Video S11). The suture sleeve should be pushed up to the puncture site and non-absorbable braided suture used to secure the lead to the muscular plane, coaxial to lead insertion to avoid kinking. It is important that the sutures be made directly to muscle including the fascia and not to subcutaneous fat. In addition to being friable, the subcutaneous plane is mobile and may result in lead dislodgment in obese patients (particularly in women with large breasts which exert a downward pull and shift this plane). It is important to use an anchor knot technique (i.e. first tie a non-slip knot on the muscle and transverse to fibre orientation) under the sleeve and then tie a loop in the groove of the suture sleeve (see Figure 11). This is the technique which offers most traction resistance149 and also prevents dislodgement from ‘ratchet’ or ‘reel’ syndrome150–152 resulting from loosening of the tie due to tissue shrinkage if the muscle and sleeve are taken together. A second suture may be placed in the same manner or simply around the sleeve to secure it to the lead. Sutures should never be placed directly on the lead body and should not be too tight as this may cause lead damage. Two or more moderately tight ties will secure the lead better than one very tight tie, with less risk of lead damage. Stability should be checked by gentle traction on the lead.

Anchor knot for securing the lead. A non-resorbable braided suture (1, 0 or 1–0) with a large curved needle should be used. Left: The lead and muscle should not be taken together for suturing the sleeve to the muscle, as tissue may necrose and shrink, resulting in loosening of the tie. Right: An anchor non-slip knot should be place on the muscle and then sutured to the sleeve. At least one addition suture should be placed, either in the same manner, or simply around the sleeve so as to further secure the lead.
Due to differences in auto-initialization methods among manufacturers, it is recommended to manually interrogate devices before implantation.153 This also allows to establish wireless communication which is useful to check proper lead connection and parameters. The lead pins should be wiped of blood with a dry swab before being connected to avoid future ‘freezing’ in the header.
The pocket may be irrigated with saline to flush out blood clots and debris. Excess lead length should be coiled in the pocket, with care being taken to avoid kinking (which may result in lead damage), and placed under the generator to avoid inadvertent damage when the pocket is reopened. The header should ideally be oriented towards the incision (see Figure 12, left), as this will facilitate access to the leads during generator change. Fixation of the generator in the pocket is optional (including for ICDs).

Closure of the pocket. Left: The leads are wrapped around and under the generator, care being taken to avoid kinks. The header is oriented towards the incision (adjacent to the deltopectoral groove in this case). Right: The pocket is closed by tying down the fascia to the muscle by separate stitches (resorbable braided suture) to imprison the generator and the leads in the pocket. The subcutaneous and epidermal layers are then sutured separately (dotted lines).

Compressive bandage to avoid haematoma. The roll and tape are placed immediately after the dressing is applied, and left until the following day.
Pocket and skin closure
The pocket should be closed by separate stitches (2–4 usually suffice) using resorbable braided suture (see Figure 12, right and Supplementary material online, Video S12). This avoids migration of the generator and the leads, as well as reduces surface wound tension in case of pocket haematoma. There are several ways of closing the skin. For example, a running stitch using resorbable 3–0 braided suture can close the subcutaneous plane followed by a subcuticular running stitch using 4–0 monofilament absorbable suture. Barbed sutures obviate the need for knots, but have not shown any significant advantage compared to standard sutures,154 and are more costly. Skin glue has been compared to sutures in two randomized studies and was found either to have no significant advantage155 or more early adverse events (9.3% vs. 6.0%; P = 0.02).156 Some operators use staples, but this has not been evaluated against sutures for PM and ICD implantation, and requires that the patient return to have them removed.
Management of perioperative complications
Although CIED implantation has some potentially fatal complications, procedure-related death is exceptionally rare (0–0.1%).17,157–159 Perioperative mortality is mainly due to comorbidities (e.g. heart failure). Perioperative complications are listed in Table 6.
Perioperative complications with PM and ICD implantation and their incidence
Complication . | Incidence . |
---|---|
Procedure-related mortality17,157–159 | 0–0.1% |
30-day mortality | 0.6–1.4% |
Pneumothorax17,42,43,135,160,178–180 | 0.4–2.8% |
Clinically relevant perforation17,84,120,135,160–165 | 0.1–1.5% |
Pericardial effusion162 | 10.2% |
Tamponade84,162 | 0.5–1.5% |
Pocket haematoma10,11,17,118,119,181 | 0.2–16.0% |
Infection7 | 0.6–3.4% |
Lead dislodgment3,45,135,160,180,187,188 | 1.2–3.3% |
Other: arrhythmias120, pleural effusion, haemothorax,120,169 aortic root perforation,124,130–133 lung perforation,171 pneumopericardium,128,170 constrictive pericarditis,168,242 air embolism,190,191 myocardial infarction,96–98,120 diaphragmatic135/intercostal172 muscle stimulation, stroke,120 brachial plexus palsy, phrenic nerve palsy,49 acute access vein thrombosis, pulmonary embole,193 allergy,238–241 damage to tricuspid valve135 | <0.5% |
Complication . | Incidence . |
---|---|
Procedure-related mortality17,157–159 | 0–0.1% |
30-day mortality | 0.6–1.4% |
Pneumothorax17,42,43,135,160,178–180 | 0.4–2.8% |
Clinically relevant perforation17,84,120,135,160–165 | 0.1–1.5% |
Pericardial effusion162 | 10.2% |
Tamponade84,162 | 0.5–1.5% |
Pocket haematoma10,11,17,118,119,181 | 0.2–16.0% |
Infection7 | 0.6–3.4% |
Lead dislodgment3,45,135,160,180,187,188 | 1.2–3.3% |
Other: arrhythmias120, pleural effusion, haemothorax,120,169 aortic root perforation,124,130–133 lung perforation,171 pneumopericardium,128,170 constrictive pericarditis,168,242 air embolism,190,191 myocardial infarction,96–98,120 diaphragmatic135/intercostal172 muscle stimulation, stroke,120 brachial plexus palsy, phrenic nerve palsy,49 acute access vein thrombosis, pulmonary embole,193 allergy,238–241 damage to tricuspid valve135 | <0.5% |
Perioperative complications with PM and ICD implantation and their incidence
Complication . | Incidence . |
---|---|
Procedure-related mortality17,157–159 | 0–0.1% |
30-day mortality | 0.6–1.4% |
Pneumothorax17,42,43,135,160,178–180 | 0.4–2.8% |
Clinically relevant perforation17,84,120,135,160–165 | 0.1–1.5% |
Pericardial effusion162 | 10.2% |
Tamponade84,162 | 0.5–1.5% |
Pocket haematoma10,11,17,118,119,181 | 0.2–16.0% |
Infection7 | 0.6–3.4% |
Lead dislodgment3,45,135,160,180,187,188 | 1.2–3.3% |
Other: arrhythmias120, pleural effusion, haemothorax,120,169 aortic root perforation,124,130–133 lung perforation,171 pneumopericardium,128,170 constrictive pericarditis,168,242 air embolism,190,191 myocardial infarction,96–98,120 diaphragmatic135/intercostal172 muscle stimulation, stroke,120 brachial plexus palsy, phrenic nerve palsy,49 acute access vein thrombosis, pulmonary embole,193 allergy,238–241 damage to tricuspid valve135 | <0.5% |
Complication . | Incidence . |
---|---|
Procedure-related mortality17,157–159 | 0–0.1% |
30-day mortality | 0.6–1.4% |
Pneumothorax17,42,43,135,160,178–180 | 0.4–2.8% |
Clinically relevant perforation17,84,120,135,160–165 | 0.1–1.5% |
Pericardial effusion162 | 10.2% |
Tamponade84,162 | 0.5–1.5% |
Pocket haematoma10,11,17,118,119,181 | 0.2–16.0% |
Infection7 | 0.6–3.4% |
Lead dislodgment3,45,135,160,180,187,188 | 1.2–3.3% |
Other: arrhythmias120, pleural effusion, haemothorax,120,169 aortic root perforation,124,130–133 lung perforation,171 pneumopericardium,128,170 constrictive pericarditis,168,242 air embolism,190,191 myocardial infarction,96–98,120 diaphragmatic135/intercostal172 muscle stimulation, stroke,120 brachial plexus palsy, phrenic nerve palsy,49 acute access vein thrombosis, pulmonary embole,193 allergy,238–241 damage to tricuspid valve135 | <0.5% |
Electronic health records or registries which capture complications are useful to keep track of these events for benchmarking or audits.
Perforation and pericarditis/tamponade
The incidence of clinically relevant lead perforation is difficult to determine due to variable definitions, but has been reported to range from 0.09% to 1.5%.17,84,120,135,160–165 Lead perforation usually manifests itself as an acute (<24 h) or sub-acute (<1 month) complication, but may rarely occur late, and even be diagnosed years after implantation.166,167 The consequences of lead perforation may be acute pericarditis, pericardial effusion or tamponade,17,84,120,160–162 constrictive pericarditis,168 pleural effusion, haemothorax,169 pneumothorax,125,127,170 lung perforation,171 abnormal electrical parameters, and diaphragmatic/intercostal stimulation,172 but it may also occur without clinical manifestations.173
Intra-operative perforation can result in vagal symptoms, chest pain, high capture thresholds, diaphragmatic capture, and inversion of the COI144 (rarely observed). Tamponade is strongly suggested by haemodynamic compromise (the differential diagnosis being a vagal reaction) and an immobile cardiac silhouette with fluoroscopy (the latter is sometimes present without effusion). Tamponade should be confirmed by echocardiography and treated with emergent pericardiocentesis. In a study including 968 patients who had an echocardiogram performed routinely before and <24 h after CIED implantation, a new mild pericardial effusion (≤10 mm in diastole) was found in as many as 8.3% of patients, with moderate (11–20 mm) and large (>20 mm) effusions in 0.4% and 1.5% of patients, respectively.162 Effusions are asymptomatic in 94% of patients,162 and therefore go unnoticed in most cases. If pain due to pericardial irritation is present, anti-inflammatory drugs can be administered. Patients with mild or moderate effusions should be monitored closely with continued surveillance after discharge to rule out recurrence/worsening of effusion. In case of haemodynamic compromise or large effusions, pericardiocentesis should be performed,162 and considered in those with moderate effusions which do not regress quickly, especially if the patient requires antiplatelet drugs and/or anticoagulation. Whether patients who require pericardiocentesis should undergo lead revision is debated. In a retrospective series of 48 patients with definitive perforations, 10 patients had pericardiocentesis for tamponade and were treated conservatively without lead revision, with recurrence of effusion over follow-up in only one patient.174 However, conservative management of perforation was associated overall with increased complications, mainly tamponade over follow-up in patients who initially had no/mild effusion (most of whom were on antiplatelet drugs and anticoagulants).174 Lead revision should therefore be carefully evaluated in patients with perforation. Most cases of lead repositioning/replacement are uneventful.174 However, perforations which are overtly transmural should be treated in centres with cardiac-thoracic surgical standby. The increased risk of infection due to early re-intervention may be mitigated by the use of an antibacterial envelope.175
Risk factors for lead perforation are shown in Table 7. Although several studies have reported increased incidence of perforation with active fixation leads,163,164,176 a recent large study showed no difference compared to passive leads.161 Nevertheless, passive atrial J-leads121,134 or VDD systems (in case atrial pacing is not necessary) can be considered in patients deemed to be at high risk of perforation, although atrial undersensing may be observed in about 10% of patients.177
Increased risk |
Older age84,120 |
Female gender84,120,162 |
Body mass index < 20163 |
Left bundle branch block120 |
Higher left ventricular ejection fraction120 |
Heart failure120 |
Steroid use163,165 |
Antiplatelet agents162 |
Temporary pacing163,165 |
Small diameter ICD leads243 |
Active fixation lead163,164,176 |
Non-single chamber device (atrial lead)120,176 |
Lateral atrial lead187 |
Apical right ventricular lead84,187 |
Longer fluoroscopy time163 |
Decreased risk |
Right ventricular systolic pressure >35mmHg163 |
Previous cardiac surgery120,162 |
Body mass index > 35163 |
Atrial fibrillation120 |
Diabetes mellitus120 |
Higher implanter procedural volume120 |
Increased risk |
Older age84,120 |
Female gender84,120,162 |
Body mass index < 20163 |
Left bundle branch block120 |
Higher left ventricular ejection fraction120 |
Heart failure120 |
Steroid use163,165 |
Antiplatelet agents162 |
Temporary pacing163,165 |
Small diameter ICD leads243 |
Active fixation lead163,164,176 |
Non-single chamber device (atrial lead)120,176 |
Lateral atrial lead187 |
Apical right ventricular lead84,187 |
Longer fluoroscopy time163 |
Decreased risk |
Right ventricular systolic pressure >35mmHg163 |
Previous cardiac surgery120,162 |
Body mass index > 35163 |
Atrial fibrillation120 |
Diabetes mellitus120 |
Higher implanter procedural volume120 |
Increased risk |
Older age84,120 |
Female gender84,120,162 |
Body mass index < 20163 |
Left bundle branch block120 |
Higher left ventricular ejection fraction120 |
Heart failure120 |
Steroid use163,165 |
Antiplatelet agents162 |
Temporary pacing163,165 |
Small diameter ICD leads243 |
Active fixation lead163,164,176 |
Non-single chamber device (atrial lead)120,176 |
Lateral atrial lead187 |
Apical right ventricular lead84,187 |
Longer fluoroscopy time163 |
Decreased risk |
Right ventricular systolic pressure >35mmHg163 |
Previous cardiac surgery120,162 |
Body mass index > 35163 |
Atrial fibrillation120 |
Diabetes mellitus120 |
Higher implanter procedural volume120 |
Increased risk |
Older age84,120 |
Female gender84,120,162 |
Body mass index < 20163 |
Left bundle branch block120 |
Higher left ventricular ejection fraction120 |
Heart failure120 |
Steroid use163,165 |
Antiplatelet agents162 |
Temporary pacing163,165 |
Small diameter ICD leads243 |
Active fixation lead163,164,176 |
Non-single chamber device (atrial lead)120,176 |
Lateral atrial lead187 |
Apical right ventricular lead84,187 |
Longer fluoroscopy time163 |
Decreased risk |
Right ventricular systolic pressure >35mmHg163 |
Previous cardiac surgery120,162 |
Body mass index > 35163 |
Atrial fibrillation120 |
Diabetes mellitus120 |
Higher implanter procedural volume120 |
Arrhythmias
Audible pulse signals from continuous ECG monitoring during an implant procedure are useful for immediately identifying arrhythmias. Transient traumatic atrioventricular block can occur during right ventricular lead positioning in patients with underlying left bundle branch block. The implanter should anticipate this complication and have cables ready to provide rescue pacing (even prior to lead fixation). Backup transcutaneous pacing should also be available. The block usually resolves within a few minutes, but in some cases may persist for several hours.
Non-sustained ventricular tachycardia is frequent during right ventricular lead placement, and especially during lead manipulation and pullback of the lead from the RVOT. In rare instances, sustained ventricular tachycardia or ventricular fibrillation is induced and may require overdrive pacing or cardioversion/defibrillation. Atrial flutter/fibrillation may also be induced during lead placement.
Preparing pre-positioned defibrillation pads on the patient is strongly recommended to prevent disrupting the sterile field to apply paddles emergently for defibrillation or transcutaneous pacing.
Analysis of arrhythmias is limited by absence of a 12-lead ECG for most standard procedures. Entrainment manoeuvres performed via the pacing system analyser (PSA) can be used to diagnose 1:1 atrioventricular arrhythmias as in the electrophysiology laboratory.
Pneumothorax
The incidence of pneumothorax ranges between 0.4% and 2.8%, and is dependent on the venous access chosen for implantation.17,42,43,135,160,178–180 Pneumothorax should be suspected if air is aspirated while advancing the needle, although this is not always the case. Fluoroscopy may visualize the pneumothorax if it is large. A routine chest X-ray should be performed within 24 h in all patients. In case of suspected pneumothorax, a chest X-ray should be performed immediately and repeated after several hours or the next day, as the complication may not be initially visible. A CT scan may also be performed if the X-ray is negative but the complication is suspected.170 In case of a small apical pneumothorax, conservative management may often suffice, with surveillance until resolution of the pneumothorax. In most other instances, a chest tube should be inserted.
Risk factors for the development of a pneumothorax include: age >80 years, female sex, low BMI, chronic obstructive pulmonary disease, and subclavian vein puncture.42,43,178 Cephalic vein cutdown or axillary vein puncture58 should be preferred to avoid this complication, and the use of a ‘Micro-Puncture’ needle can minimize damage to the lung.
Pocket haematoma
The incidence of pocket haematoma ranges between 0.2% and 16.0% depending on definition and factors such as anticoagulation regimen.10,11,17,118,119,181 It is associated with an approximately nine-fold increased risk of infection.7
Conservative management should be favoured if possible due to 15-fold risk of infection with reintervention.28 However, in cases of wound dehiscence or skin erosion, severe pain, arm swelling, brachial plexus or arterial compromise, a surgical revision should be performed without delay. The procedure should be performed with the strictest precautionary measures by an experienced implanter and use of an antibacterial envelope should be considered. Needle aspiration is contra-indicated as it provides incomplete evacuation and may result in infection by seeding the pocket.
Pocket haematoma should be avoided by optimal perioperative management of anticoagulation and antiplatelet drugs (see Section Preoperative preparation and Table 3). In addition, good surgical technique with minimal tissue trauma, respecting anatomical planes and with meticulous attention paid to haemostasis should be the norm. Haemostatic resorbable sutures may be placed at venous entry sites (non-resorbable sutures may hamper future lead extraction, if required). Use of a suction drain has been described,182 but is controversial due to concern for infection. There is little evidence that haemostatic agents are effective.183 Compression using sandbags, tapes or vests184–186 can be useful to avoid haematoma.
Local and systemic CIED infection
CIED infection is a serious and potentially life-threatening complication. The incidence is reported to be 0.6–3.4%.7 Detailed description on diagnosis, treatment and prevention can be found in a recent EHRA consensus document.7
Lead dislodgement
Lead dislodgment is reported in 1.2–3.3% of implantations.3,45,135,160,180,187,188 Most dislodgments occur before discharge.187 The incidence is significantly higher for atrial leads than for right ventricular leads.45,180,187 There is a trend towards fewer dislodgments with active fixation leads compared to passive leads.135 Diagnosis is usually confirmed by the chest X-ray after abnormal electrical testing, but micro-dislodgments may not be apparent. Dislodgement usually requires revision, but may be unnecessary if lead function is not compromised or the lead is not absolutely required and there are no adverse effects, such as arrhythmia or lead chatter. If repositioning is necessary, it should be deferred if possible for a few weeks to minimize pain and risk of infection.7
Other complications
Inadvertent arterial puncture should be identified before insertion of the sheath by observing pulsatile flow, bright red blood, or guidewire position. Simple compression is usually sufficient, but a vascular closure device or surgical revision may be necessary if the sheath was introduced.189
Air embolism can cause haemodynamic compromise and is potentially lethal.190,191 It is favoured by snoring or deep breathing and can be avoided by the operator temporarily blocking the sheath with a finger and introducing the lead during a breath-hold/expiration, or by using sheaths with haemostatic valves. Fluoroscopy shows air in the right ventricle and pulmonary artery. Patients may be asymptomatic or complain of dyspnoea. Patients should be placed in a Trendelenburg position, administered 100% oxygen, and if necessary, the air should be aspirated (e.g. with a pigtail or Judkins right diagnostic catheter).
Pneumopericardium may occur as a consequence of atrial lead perforation with right-sided pneumothorax.192 The diagnosis may be missed on the chest X-ray and may require a CT scan.170 The issue resolves with drainage of the pneumothorax.
Acute deep vein thrombosis of the access vein may rarely occur within days of implantation,193 or after months194 or years and may in rare instances be associated with pulmonary embolism. The symptoms usually resolve with administration of heparin, followed by oral anticoagulation.
Postoperative management
A chest X-ray (postero-anterior and lateral) should be performed within 24 h in all patients after lead implantation to rule out pneumothorax and document lead position. A 12-lead ECG should be recorded and the device fully checked before discharge.
Patients may be mobilized freely once they have recovered from sedation, and same-day discharge is feasible in selected patients.195 There is no evidence that limitation of arm movement after implantation avoids dislodgment, as securing by fibrosis requires months. A study randomizing standard care (restriction of abduction and lifting of weights for 6 weeks) vs. shoulder exercises, found significantly less shoulder pain at 1 month in the latter group (33% vs. 5%, P = 0.02).196 For this reason, use of arm slings should be avoided.
The patient should be informed regarding post-operative care, ideally with written instructions. The wound should be properly covered by a dressing for 2–10 days. The patient may shower if he has a waterproof dressing, or otherwise after about a week and clean the upper body with a moist towel in the meantime. Routine wound inspection is not superior to patient-initiated consultation.197 Patients should be seen in-office at 1–3 months, as delaying to >12 weeks is associated with adverse outcome.198 Remote monitoring can be useful for early detection of technical issues.199
Specific considerations for ICD implantation
Implantation of ICDs follows the same steps as for PMs However, specific aspects deserve consideration. Left-sided implantation should be favoured due to risk of increased DFT and total mortality with right-sided access (although co-morbidities requiring right-sided access, such as haemodialysis or cancer may have confounded outcome).200–202 Defibrillation testing is already covered in the 2015 Heart Rhythm Society (HRS)/EHRA/Asia Pacific Heart Rhythm Society(APHRS)/SOLAECE expert consensus statement on optimal ICD programming and testing,203 without new data which requires modifying these recommendations.
Signal quality
Atrial and ventricular signal quality is of particular importance for rhythm discrimination algorithms to work properly. For example, atrial undersensing during a supra-ventricular tachycardia will fulfil the V > A criterion with misdiagnosis of ventricular tachycardia. Low R-wave amplitude may result in undersensing of ventricular arrhythmias and increases risk of T-wave oversensing due to automatic sensitivity gain levels starting as a percentage of the sensed amplitude. Sensed R-wave amplitude measured by the PSA may not correspond to that of the generator, due to differences in filter settings and regression of COI. It is therefore useful to check signal amplitude detected via the generator before closing the pocket.
The coil of integrated bipolar leads are part of the sensing circuit and records atrial signals in as many as 11% of patients if it lies close to the tricuspid annulus,204 with a risk of double-counting and inappropriate therapy. The ventricular electrogram should therefore be scrutinized for presence of low-amplitude atrial signals when implanting these leads.
As with any procedure involving abandoned leads, care should be taken to avoid chatter with pre-existing leads which can result in spurious arrhythmia detection or inhibition of pacing. This is particularly important with integrated bipolar leads which may be more prone to this phenomenon. In an in vitro setting, only metal-metal interaction resulted in chatter, which was prevented by expanded polytetrafluoroethylene coating of the coil.205 Coil coating also reduces fibrous adhesions which facilitate lead extraction.206,207
It is advisable to implant ICD leads and generators from the same manufacturer to preserve labelled magnetic resonance imaging (MRI)-conditionality. In addition, manufacturer-specific signal processing and lead sensing may result in detection issues.208 Furthermore, elevation of subthreshold impedance values have been reported due to contact interface oxidation between lead pins and set screws that may be of different materials not tested for compatibility.209
Right ventricular lead position
Three studies with a total of 146 patients have randomized ICD lead position between the RVOT and RVA, and found no meaningful differences in DFT, with similar threshold measurements.210–212 Two larger studies randomized RVS and RVA ICD lead position, and found no significant differences in outcome between groups. However, in the SPICE study90 (which included 299 patients), the RVS group tended to have a higher rate of DFT > 25J (5.0% vs. 2.1%, P = 0.21) and a higher rate of ICD lead revisions (6.9% vs. 3.2%, P = 0.57). In the SEPTAL study,213 which included 215 patients, the RVS group tended to have a higher incidence of total mortality (7.9% vs. 2.9%, P = NS). The main issue with these studies is that ‘mid-septal’ lead position was only verified in the LAO view, which is insufficient, as mentioned previously.91,94,95 It is therefore likely that many leads were implanted in the anterior free wall and that a true septal position for ICD leads has not been properly validated. For these reasons, it may be preferable to implant ICD leads in the RVA, but alternative sites may be considered in case of suboptimal electrical parameters, or to avoid cardiac perforation associated with thin ICD leads120 and certain patient characteristics (see Table 7).
Single-coil vs. dual-coil ICD leads
There has been a shift away from dual-coil ICD leads due to difficult and more risky lead extraction as a result of the proximal coil being fibrosed to the superior vena cava.206,214 In a meta-analysis of 16 studies, there was a clinically irrelevant reduction in DFT with dual-coil leads (mean 0.81 J, 95% CI 0.31–1.30 J) and no difference in first shock efficacy.215 Nevertheless, dual-coil leads may have a higher shock conversion rate of atrial arrhythmias (44.0% vs. 28.8%, P = 0.07 in the SIMPLE study216) and offer additional morphology vectors for rhythm discrimination. Also, selected patients with right-sided ICD implants may benefit from dual-coil leads.200
DF-4 vs. DF-1 connector
The DF-4 standard is popular with implanting physicians as it facilitates lead connection. However, it offers fewer options compared to DF-1 leads, such as the requirement to implant a pacing lead when ‘downgrading’ from an ICD to a PM (e.g. during generator replacement in super-responders to CRT). There is also no possibility (without an adaptor) to implant stand-alone coils (e.g. in the azygos vein) or SQ-arrays in case of a high DFT, or to switch IS-1 connector pins with left ventricular leads during generator replacements in patients with functional recalled leads.217,218
Specific considerations with generator replacement
The REPLACE registry119 provides prospective data in 1750 patients who underwent elective generator replacements. The rate of major adverse events at 6 months’ follow-up was 4.0% (generator replacement only) and 15.3% (with addition of a lead). Most complications were lead dislodgment or malfunction, haematoma and infection. Generator replacements are often performed by a junior physician alone, which is questionable given these high rates of adverse events.
The patient’s left ventricular ejection fraction should be known, as a generator replacement is an excellent opportunity for device upgrade (to an ICD or CRT219–221) or if downgrade from CRT-D to CRT-P is considered in case of super-response or aging of the patient. Electrical parameters recorded over follow-up should be known, in order to compare them with current findings. In patients with very old leads, it is useful to check the connector standard of the lead (e.g. 5 mm or LV-1) and ensure that the required hardware is available. It is also advisable to determine if any leads are on recall or alert, as abandonment or extraction with replacement vs. continued use needs to be considered before the patient is scheduled for a procedure. Abandoned leads may either be capped or sectioned (care being taken to avoid extrusion of metallic components and also to avoid blood clogging the lumen, which may compromise future extraction). This may be achieved by pulling lead insulation over the sectioned tip or knuckling the extremity, and then fastening a tie. Abandonned leads should be fixated in the pocket to prevent them from migrating under the skin. In patients with a dual-chamber system who have developed permanent AF, alternatives are to either maintain a dual-chamber device to preserve MRI-conditionality, or to abandon the atrial lead.
Patients who are PM-dependent usually have an escape rhythm which emerges after some time spent in VVI 30 b.p.m. Otherwise isoprenaline (1–10 µg/min) will solve this issue in almost all cases and avoid need for temporary pacing.
It is recommended that an X-ray or high-resolution fluoroscopy be done prior to skin incision to evaluate lead damage, with particular attention being paid to the subclavian region, site of fixation sleeves, and along the leads, particularly in specific situations (e.g. conductor externalization of Riata leads). This will also yield information on presence of abandoned leads (which is relevant for MRI-conditionality) and position of the header and leads in the pocket. Independently of the initial incision, access should be performed about 1 cm lateral or superior from the current pocket (and never over the generator) to avoid damaging the leads and to provide a margin between skin closure and the pocket in case of pocket haematoma or superficial infection. The incision may be performed over the initial scar if this is desirable for cosmetic reasons, as long as the scar does not lie over the pocket.
When dissecting fibrotic tissue around the leads, electrocautery may be used in cut mode at low energy settings parallel to the course of the lead without prolonged applications at a fixed position. Improper use of electrocautery may result in thermal damage to the insulation, the risk of which can be reduced using a plasma surgery tool.222 Electrocautery should be used with extreme caution over the generator (and should not come into contact with the metallic housing) or conductor coil in case of lead insulation failure, as it may induce ventricular arrhythmia.223–225
Leads may be frozen to the header and can be freed using an orthopaedic drill226,227 or scalpel228 (to access the tip from the rear of the header and push out the lead with the wrench), bone cutter229 or by injecting a solvent (pure ethanol) into the header with a needle.230 It is also possible to inject lubricant around the pin after removing the setscrew.229 It is important to avoid this issue by ensuring that lead pins are clean of blood before insertion in the header. The set screw may be frozen, which may require an Allen key to be unscrewed. If the set screw is stripped such that the wrench cannot provide the needed torque, it is sometimes possible to remove the silicone grommet and grasp and turn the set screw from the sides using a small clamp.
In some patients, lead damage may be visualized, and it may be difficult to implant a new lead (e.g. in case of vein obstruction or in a frail patient). It is useful in these instances to have repair kits with silicone sleeves and glue, and tools for lead splicing (e.g. Medtronic 5866–9 M Adaptor, which can be used for salvaging a fractured lead).231,232
Conclusions
Tools and techniques for device implantation have evolved over the years, as has education in this field. Virtual reality simulators are increasingly used to train device implantation in a safe environment233–235 and are useful adjuncts for education. This document provides a framework for standardizing PM and ICD implantation. Ultimately, by standardizing the procedure and avoiding poor techniques, the document should serve to improve patient outcome.
Consensus statement tables
Statement . | Class . | Evidence . |
---|---|---|
Device indication should be based upon current guidelines and take into account the patient’s specific needs. | ![]() | E |
The operation room/catheterization or electrophysiology laboratory must meet aseptic standards for foreign body implants and be ventilated with >15 air changes/h (ideally 20–25 changes/h).13,14 | ![]() | O |
The procedure should be performed or supervised by a proficient physician, with EHRA level 2 or national certification, or equivalent expertise. | ![]() | E |
At least one unscrubbed allied professional or nurse should assist the implanter with the procedure. | ![]() | E |
Anaesthesia standby should be readily available. | ![]() | E |
The operator, or another physician present on site, should be able to perform emergency pericardiocentesis. | ![]() | E |
Exposure to irradiation should be minimized. | ![]() | E |
Statement . | Class . | Evidence . |
---|---|---|
Device indication should be based upon current guidelines and take into account the patient’s specific needs. | ![]() | E |
The operation room/catheterization or electrophysiology laboratory must meet aseptic standards for foreign body implants and be ventilated with >15 air changes/h (ideally 20–25 changes/h).13,14 | ![]() | O |
The procedure should be performed or supervised by a proficient physician, with EHRA level 2 or national certification, or equivalent expertise. | ![]() | E |
At least one unscrubbed allied professional or nurse should assist the implanter with the procedure. | ![]() | E |
Anaesthesia standby should be readily available. | ![]() | E |
The operator, or another physician present on site, should be able to perform emergency pericardiocentesis. | ![]() | E |
Exposure to irradiation should be minimized. | ![]() | E |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Statement . | Class . | Evidence . |
---|---|---|
Device indication should be based upon current guidelines and take into account the patient’s specific needs. | ![]() | E |
The operation room/catheterization or electrophysiology laboratory must meet aseptic standards for foreign body implants and be ventilated with >15 air changes/h (ideally 20–25 changes/h).13,14 | ![]() | O |
The procedure should be performed or supervised by a proficient physician, with EHRA level 2 or national certification, or equivalent expertise. | ![]() | E |
At least one unscrubbed allied professional or nurse should assist the implanter with the procedure. | ![]() | E |
Anaesthesia standby should be readily available. | ![]() | E |
The operator, or another physician present on site, should be able to perform emergency pericardiocentesis. | ![]() | E |
Exposure to irradiation should be minimized. | ![]() | E |
Statement . | Class . | Evidence . |
---|---|---|
Device indication should be based upon current guidelines and take into account the patient’s specific needs. | ![]() | E |
The operation room/catheterization or electrophysiology laboratory must meet aseptic standards for foreign body implants and be ventilated with >15 air changes/h (ideally 20–25 changes/h).13,14 | ![]() | O |
The procedure should be performed or supervised by a proficient physician, with EHRA level 2 or national certification, or equivalent expertise. | ![]() | E |
At least one unscrubbed allied professional or nurse should assist the implanter with the procedure. | ![]() | E |
Anaesthesia standby should be readily available. | ![]() | E |
The operator, or another physician present on site, should be able to perform emergency pericardiocentesis. | ![]() | E |
Exposure to irradiation should be minimized. | ![]() | E |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Supplementary material
Supplementary material is available at Europace online.
Consensus statements . | Class . | Evidence . |
---|---|---|
Perioperative prevention measures performed according to 2019 EHRA consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections.7 | ![]() | E |
Provide adequate sedation and local anaesthesia, within dosage limits (e.g. lidocaine 4.5 mg/kg).22 | ![]() | O |
Pocket created at the beginning of the procedure in case of new implants. | ![]() | E |
Subfascial prepectoral (subcutaneous) pocket is preferred over submuscular pocket. | ![]() | E |
Submuscular pocket may be useful in patients with low BMI, as they are at risk for pocket erosion, or for cosmetic reasons. | ![]() | E |
Axillary vein puncture or cephalic venous cutdown are preferred for venous access.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian puncture should not be used as a first-line measure due to the risk of pneumothorax and lead failure.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian vein puncture may be used in case of failed axillary and cephalic vein access. | ![]() | E |
A fluoroscopically-guided axillary vein puncture aiming for region of the first rib or guided by ultrasound may be performed.41,58–62,64 | ![]() | O |
Caudal 35° tilt to minimize risk of pneumothorax may be used for axillary vein puncture.58 | ![]() | O |
A venogram should be performed for venous access in case of failed puncture using other landmarks, or as a first-line approach during training or in patients at high risk of pneumothorax.30,50,54,55 | ![]() | O |
Venoplasty may be considered in case of venous stenosis/obstruction.69,71 | ![]() | O |
Both active- and passive-fixation leads may be used for ventricular pacing, but active leads should be used when targeting the lead on the interventricular septum. | ![]() | O |
Electrical parameters for right ventricular leads at implantation should aim for a capture threshold of <1.5 V/0.5 ms, a sensing amplitude of at least 4 mV, and impedance within normal limits for the lead. | ![]() | E |
The anterior right atrial appendage should be the preferred as a first-line approach for atrial pacing, with alternative pacing sites in case of lead implantation (e.g. poor stability or electrical parameters). | ![]() | E |
A passive J-shaped lead may be used as an alternative to active fixation lead to avoid atrial perforation.121,134 | ![]() | O |
Multiple fluoroscopic views may be used routinely for implanting right atrial leads. | ![]() | E |
Electrical parameters at atrial lead implantation should aim for capture threshold <1.5 V/0.5 ms, >1.5 mV sensing amplitude, far-field R-wave <20% of P-wave amplitude, and impedances within normal limits for the lead. | ![]() | E |
For active-fixation leads, helix extension should be based upon specific fluoroscopic markers, and not the number of rotations. | ![]() | E |
For active-fixation leads, a clear current of injury should be visualized.145–148 | ![]() | O |
Leads should be fixated to the fascia and muscle using an anchor knot with additional ties to secure the sleeve to the lead.149 | ![]() | E |
The generator may be optionally fixated to the muscular plane. | ![]() | E |
The pocket should be closed to prevent migration of the leads and the generator. | ![]() | E |
Consensus statements . | Class . | Evidence . |
---|---|---|
Perioperative prevention measures performed according to 2019 EHRA consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections.7 | ![]() | E |
Provide adequate sedation and local anaesthesia, within dosage limits (e.g. lidocaine 4.5 mg/kg).22 | ![]() | O |
Pocket created at the beginning of the procedure in case of new implants. | ![]() | E |
Subfascial prepectoral (subcutaneous) pocket is preferred over submuscular pocket. | ![]() | E |
Submuscular pocket may be useful in patients with low BMI, as they are at risk for pocket erosion, or for cosmetic reasons. | ![]() | E |
Axillary vein puncture or cephalic venous cutdown are preferred for venous access.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian puncture should not be used as a first-line measure due to the risk of pneumothorax and lead failure.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian vein puncture may be used in case of failed axillary and cephalic vein access. | ![]() | E |
A fluoroscopically-guided axillary vein puncture aiming for region of the first rib or guided by ultrasound may be performed.41,58–62,64 | ![]() | O |
Caudal 35° tilt to minimize risk of pneumothorax may be used for axillary vein puncture.58 | ![]() | O |
A venogram should be performed for venous access in case of failed puncture using other landmarks, or as a first-line approach during training or in patients at high risk of pneumothorax.30,50,54,55 | ![]() | O |
Venoplasty may be considered in case of venous stenosis/obstruction.69,71 | ![]() | O |
Both active- and passive-fixation leads may be used for ventricular pacing, but active leads should be used when targeting the lead on the interventricular septum. | ![]() | O |
Electrical parameters for right ventricular leads at implantation should aim for a capture threshold of <1.5 V/0.5 ms, a sensing amplitude of at least 4 mV, and impedance within normal limits for the lead. | ![]() | E |
The anterior right atrial appendage should be the preferred as a first-line approach for atrial pacing, with alternative pacing sites in case of lead implantation (e.g. poor stability or electrical parameters). | ![]() | E |
A passive J-shaped lead may be used as an alternative to active fixation lead to avoid atrial perforation.121,134 | ![]() | O |
Multiple fluoroscopic views may be used routinely for implanting right atrial leads. | ![]() | E |
Electrical parameters at atrial lead implantation should aim for capture threshold <1.5 V/0.5 ms, >1.5 mV sensing amplitude, far-field R-wave <20% of P-wave amplitude, and impedances within normal limits for the lead. | ![]() | E |
For active-fixation leads, helix extension should be based upon specific fluoroscopic markers, and not the number of rotations. | ![]() | E |
For active-fixation leads, a clear current of injury should be visualized.145–148 | ![]() | O |
Leads should be fixated to the fascia and muscle using an anchor knot with additional ties to secure the sleeve to the lead.149 | ![]() | E |
The generator may be optionally fixated to the muscular plane. | ![]() | E |
The pocket should be closed to prevent migration of the leads and the generator. | ![]() | E |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
Perioperative prevention measures performed according to 2019 EHRA consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections.7 | ![]() | E |
Provide adequate sedation and local anaesthesia, within dosage limits (e.g. lidocaine 4.5 mg/kg).22 | ![]() | O |
Pocket created at the beginning of the procedure in case of new implants. | ![]() | E |
Subfascial prepectoral (subcutaneous) pocket is preferred over submuscular pocket. | ![]() | E |
Submuscular pocket may be useful in patients with low BMI, as they are at risk for pocket erosion, or for cosmetic reasons. | ![]() | E |
Axillary vein puncture or cephalic venous cutdown are preferred for venous access.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian puncture should not be used as a first-line measure due to the risk of pneumothorax and lead failure.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian vein puncture may be used in case of failed axillary and cephalic vein access. | ![]() | E |
A fluoroscopically-guided axillary vein puncture aiming for region of the first rib or guided by ultrasound may be performed.41,58–62,64 | ![]() | O |
Caudal 35° tilt to minimize risk of pneumothorax may be used for axillary vein puncture.58 | ![]() | O |
A venogram should be performed for venous access in case of failed puncture using other landmarks, or as a first-line approach during training or in patients at high risk of pneumothorax.30,50,54,55 | ![]() | O |
Venoplasty may be considered in case of venous stenosis/obstruction.69,71 | ![]() | O |
Both active- and passive-fixation leads may be used for ventricular pacing, but active leads should be used when targeting the lead on the interventricular septum. | ![]() | O |
Electrical parameters for right ventricular leads at implantation should aim for a capture threshold of <1.5 V/0.5 ms, a sensing amplitude of at least 4 mV, and impedance within normal limits for the lead. | ![]() | E |
The anterior right atrial appendage should be the preferred as a first-line approach for atrial pacing, with alternative pacing sites in case of lead implantation (e.g. poor stability or electrical parameters). | ![]() | E |
A passive J-shaped lead may be used as an alternative to active fixation lead to avoid atrial perforation.121,134 | ![]() | O |
Multiple fluoroscopic views may be used routinely for implanting right atrial leads. | ![]() | E |
Electrical parameters at atrial lead implantation should aim for capture threshold <1.5 V/0.5 ms, >1.5 mV sensing amplitude, far-field R-wave <20% of P-wave amplitude, and impedances within normal limits for the lead. | ![]() | E |
For active-fixation leads, helix extension should be based upon specific fluoroscopic markers, and not the number of rotations. | ![]() | E |
For active-fixation leads, a clear current of injury should be visualized.145–148 | ![]() | O |
Leads should be fixated to the fascia and muscle using an anchor knot with additional ties to secure the sleeve to the lead.149 | ![]() | E |
The generator may be optionally fixated to the muscular plane. | ![]() | E |
The pocket should be closed to prevent migration of the leads and the generator. | ![]() | E |
Consensus statements . | Class . | Evidence . |
---|---|---|
Perioperative prevention measures performed according to 2019 EHRA consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections.7 | ![]() | E |
Provide adequate sedation and local anaesthesia, within dosage limits (e.g. lidocaine 4.5 mg/kg).22 | ![]() | O |
Pocket created at the beginning of the procedure in case of new implants. | ![]() | E |
Subfascial prepectoral (subcutaneous) pocket is preferred over submuscular pocket. | ![]() | E |
Submuscular pocket may be useful in patients with low BMI, as they are at risk for pocket erosion, or for cosmetic reasons. | ![]() | E |
Axillary vein puncture or cephalic venous cutdown are preferred for venous access.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian puncture should not be used as a first-line measure due to the risk of pneumothorax and lead failure.29–31,37,40,41 | ![]() | R, M |
Intrathoracic subclavian vein puncture may be used in case of failed axillary and cephalic vein access. | ![]() | E |
A fluoroscopically-guided axillary vein puncture aiming for region of the first rib or guided by ultrasound may be performed.41,58–62,64 | ![]() | O |
Caudal 35° tilt to minimize risk of pneumothorax may be used for axillary vein puncture.58 | ![]() | O |
A venogram should be performed for venous access in case of failed puncture using other landmarks, or as a first-line approach during training or in patients at high risk of pneumothorax.30,50,54,55 | ![]() | O |
Venoplasty may be considered in case of venous stenosis/obstruction.69,71 | ![]() | O |
Both active- and passive-fixation leads may be used for ventricular pacing, but active leads should be used when targeting the lead on the interventricular septum. | ![]() | O |
Electrical parameters for right ventricular leads at implantation should aim for a capture threshold of <1.5 V/0.5 ms, a sensing amplitude of at least 4 mV, and impedance within normal limits for the lead. | ![]() | E |
The anterior right atrial appendage should be the preferred as a first-line approach for atrial pacing, with alternative pacing sites in case of lead implantation (e.g. poor stability or electrical parameters). | ![]() | E |
A passive J-shaped lead may be used as an alternative to active fixation lead to avoid atrial perforation.121,134 | ![]() | O |
Multiple fluoroscopic views may be used routinely for implanting right atrial leads. | ![]() | E |
Electrical parameters at atrial lead implantation should aim for capture threshold <1.5 V/0.5 ms, >1.5 mV sensing amplitude, far-field R-wave <20% of P-wave amplitude, and impedances within normal limits for the lead. | ![]() | E |
For active-fixation leads, helix extension should be based upon specific fluoroscopic markers, and not the number of rotations. | ![]() | E |
For active-fixation leads, a clear current of injury should be visualized.145–148 | ![]() | O |
Leads should be fixated to the fascia and muscle using an anchor knot with additional ties to secure the sleeve to the lead.149 | ![]() | E |
The generator may be optionally fixated to the muscular plane. | ![]() | E |
The pocket should be closed to prevent migration of the leads and the generator. | ![]() | E |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
Left-sided implantation of ICDs should be favoured due to lower defibrillation thresholds (and non-dominance for most patients).200,201 | ![]() | O |
Defibrillation testing is optional and may be reserved for special circumstances.203,244,245 | ![]() | R, M |
Single coil ICD leads should be used in most instances to avoid adhesions of the proximal coil which make extraction more difficult.206,214 | ![]() | O |
Dual-coil ICD leads may be useful in specific situations (e.g. high defibrillation thresholds, right-sided implantations, more options for morphology templates etc.).200,215 | ![]() | O |
Consensus statements . | Class . | Evidence . |
---|---|---|
Left-sided implantation of ICDs should be favoured due to lower defibrillation thresholds (and non-dominance for most patients).200,201 | ![]() | O |
Defibrillation testing is optional and may be reserved for special circumstances.203,244,245 | ![]() | R, M |
Single coil ICD leads should be used in most instances to avoid adhesions of the proximal coil which make extraction more difficult.206,214 | ![]() | O |
Dual-coil ICD leads may be useful in specific situations (e.g. high defibrillation thresholds, right-sided implantations, more options for morphology templates etc.).200,215 | ![]() | O |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
Left-sided implantation of ICDs should be favoured due to lower defibrillation thresholds (and non-dominance for most patients).200,201 | ![]() | O |
Defibrillation testing is optional and may be reserved for special circumstances.203,244,245 | ![]() | R, M |
Single coil ICD leads should be used in most instances to avoid adhesions of the proximal coil which make extraction more difficult.206,214 | ![]() | O |
Dual-coil ICD leads may be useful in specific situations (e.g. high defibrillation thresholds, right-sided implantations, more options for morphology templates etc.).200,215 | ![]() | O |
Consensus statements . | Class . | Evidence . |
---|---|---|
Left-sided implantation of ICDs should be favoured due to lower defibrillation thresholds (and non-dominance for most patients).200,201 | ![]() | O |
Defibrillation testing is optional and may be reserved for special circumstances.203,244,245 | ![]() | R, M |
Single coil ICD leads should be used in most instances to avoid adhesions of the proximal coil which make extraction more difficult.206,214 | ![]() | O |
Dual-coil ICD leads may be useful in specific situations (e.g. high defibrillation thresholds, right-sided implantations, more options for morphology templates etc.).200,215 | ![]() | O |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
The patient’s clinical status and left ventricular ejection fraction should be known before generator replacement, in order to evaluate requirement for upgrade to ICD and/or CRT.219–221 | ![]() | E |
Lead connector pin standards should be verified routinely before generator change. | ![]() | E |
An X-ray or high-resolution fluoroscopy should be routinely performed prior to generator replacement to check for lead integrity. | ![]() | E |
Electrocautery should be used with extreme caution near the generator or in case of lead insulation failure, as this can induce life-threatening ventricular arrhythmias.223–225 | ![]() | O |
Consensus statements . | Class . | Evidence . |
---|---|---|
The patient’s clinical status and left ventricular ejection fraction should be known before generator replacement, in order to evaluate requirement for upgrade to ICD and/or CRT.219–221 | ![]() | E |
Lead connector pin standards should be verified routinely before generator change. | ![]() | E |
An X-ray or high-resolution fluoroscopy should be routinely performed prior to generator replacement to check for lead integrity. | ![]() | E |
Electrocautery should be used with extreme caution near the generator or in case of lead insulation failure, as this can induce life-threatening ventricular arrhythmias.223–225 | ![]() | O |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
The patient’s clinical status and left ventricular ejection fraction should be known before generator replacement, in order to evaluate requirement for upgrade to ICD and/or CRT.219–221 | ![]() | E |
Lead connector pin standards should be verified routinely before generator change. | ![]() | E |
An X-ray or high-resolution fluoroscopy should be routinely performed prior to generator replacement to check for lead integrity. | ![]() | E |
Electrocautery should be used with extreme caution near the generator or in case of lead insulation failure, as this can induce life-threatening ventricular arrhythmias.223–225 | ![]() | O |
Consensus statements . | Class . | Evidence . |
---|---|---|
The patient’s clinical status and left ventricular ejection fraction should be known before generator replacement, in order to evaluate requirement for upgrade to ICD and/or CRT.219–221 | ![]() | E |
Lead connector pin standards should be verified routinely before generator change. | ![]() | E |
An X-ray or high-resolution fluoroscopy should be routinely performed prior to generator replacement to check for lead integrity. | ![]() | E |
Electrocautery should be used with extreme caution near the generator or in case of lead insulation failure, as this can induce life-threatening ventricular arrhythmias.223–225 | ![]() | O |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
Effusions which are large (>20 mm in diastole) or of any size when causing haemodynamic compromise should be treated with pericardiocentesis.162 | ![]() | O |
Moderate effusions (11–20 mm in diastole) which do not regress quickly may be treated by pericardiocentesis. | ![]() | E |
Patients with stable mild effusions (<10 mm in diastole) should be monitored closely with continued surveillance after discharge to rule out recurrence/worsening of effusion.162 | ![]() | O |
Lead revision may be indicated in selected patients in case of perforation, especially those requiring antiplatelets and/or anticoagulants, as conservative management is associated with increased complications174 | ![]() | O |
Pneumothorax should be drained with a chest tube unless it is small or regresses in a few days. | ![]() | E |
Haematomas should be conservatively treated unless there is wound dehiscence or skin erosion, severe pain, arm swelling or brachial plexus/arterial compromise, when surgical revision should be performed without delay. | ![]() | E |
Needle aspiration should not be performed to evacuate a haematoma. | ![]() | E |
Consensus statements . | Class . | Evidence . |
---|---|---|
Effusions which are large (>20 mm in diastole) or of any size when causing haemodynamic compromise should be treated with pericardiocentesis.162 | ![]() | O |
Moderate effusions (11–20 mm in diastole) which do not regress quickly may be treated by pericardiocentesis. | ![]() | E |
Patients with stable mild effusions (<10 mm in diastole) should be monitored closely with continued surveillance after discharge to rule out recurrence/worsening of effusion.162 | ![]() | O |
Lead revision may be indicated in selected patients in case of perforation, especially those requiring antiplatelets and/or anticoagulants, as conservative management is associated with increased complications174 | ![]() | O |
Pneumothorax should be drained with a chest tube unless it is small or regresses in a few days. | ![]() | E |
Haematomas should be conservatively treated unless there is wound dehiscence or skin erosion, severe pain, arm swelling or brachial plexus/arterial compromise, when surgical revision should be performed without delay. | ![]() | E |
Needle aspiration should not be performed to evacuate a haematoma. | ![]() | E |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials
Consensus statements . | Class . | Evidence . |
---|---|---|
Effusions which are large (>20 mm in diastole) or of any size when causing haemodynamic compromise should be treated with pericardiocentesis.162 | ![]() | O |
Moderate effusions (11–20 mm in diastole) which do not regress quickly may be treated by pericardiocentesis. | ![]() | E |
Patients with stable mild effusions (<10 mm in diastole) should be monitored closely with continued surveillance after discharge to rule out recurrence/worsening of effusion.162 | ![]() | O |
Lead revision may be indicated in selected patients in case of perforation, especially those requiring antiplatelets and/or anticoagulants, as conservative management is associated with increased complications174 | ![]() | O |
Pneumothorax should be drained with a chest tube unless it is small or regresses in a few days. | ![]() | E |
Haematomas should be conservatively treated unless there is wound dehiscence or skin erosion, severe pain, arm swelling or brachial plexus/arterial compromise, when surgical revision should be performed without delay. | ![]() | E |
Needle aspiration should not be performed to evacuate a haematoma. | ![]() | E |
Consensus statements . | Class . | Evidence . |
---|---|---|
Effusions which are large (>20 mm in diastole) or of any size when causing haemodynamic compromise should be treated with pericardiocentesis.162 | ![]() | O |
Moderate effusions (11–20 mm in diastole) which do not regress quickly may be treated by pericardiocentesis. | ![]() | E |
Patients with stable mild effusions (<10 mm in diastole) should be monitored closely with continued surveillance after discharge to rule out recurrence/worsening of effusion.162 | ![]() | O |
Lead revision may be indicated in selected patients in case of perforation, especially those requiring antiplatelets and/or anticoagulants, as conservative management is associated with increased complications174 | ![]() | O |
Pneumothorax should be drained with a chest tube unless it is small or regresses in a few days. | ![]() | E |
Haematomas should be conservatively treated unless there is wound dehiscence or skin erosion, severe pain, arm swelling or brachial plexus/arterial compromise, when surgical revision should be performed without delay. | ![]() | E |
Needle aspiration should not be performed to evacuate a haematoma. | ![]() | E |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials
Consensus statements . | Class . | Evidence . |
---|---|---|
A chest X-ray (postero-anterior and if possible lateral) should be performed in all patients after lead implantation and before discharge to rule out pneumothorax and document lead position. | ![]() | E |
Patients can be mobilized freely after device implantation once they have recovered from sedation. | ![]() | E |
Compression using sandbags, tapes or vests can be useful to avoid haematoma.184–186 | ![]() | O |
Patients do not need to restrict arm movements after device implantation, as this has not been shown to reduce risk of lead dislodgment and may increase shoulder pain.196 | ![]() | O |
The wound should be properly covered for 2–10 days, ideally with a waterproof dressing. | ![]() | E |
After discharge, patient-initiated consultation in case of problems may be sufficient in most cases (i.e. instead of routine wound inspection).197 | ![]() | O |
Patients should be seen in-office within 2–12 weeks.198 | ![]() | O |
Consensus statements . | Class . | Evidence . |
---|---|---|
A chest X-ray (postero-anterior and if possible lateral) should be performed in all patients after lead implantation and before discharge to rule out pneumothorax and document lead position. | ![]() | E |
Patients can be mobilized freely after device implantation once they have recovered from sedation. | ![]() | E |
Compression using sandbags, tapes or vests can be useful to avoid haematoma.184–186 | ![]() | O |
Patients do not need to restrict arm movements after device implantation, as this has not been shown to reduce risk of lead dislodgment and may increase shoulder pain.196 | ![]() | O |
The wound should be properly covered for 2–10 days, ideally with a waterproof dressing. | ![]() | E |
After discharge, patient-initiated consultation in case of problems may be sufficient in most cases (i.e. instead of routine wound inspection).197 | ![]() | O |
Patients should be seen in-office within 2–12 weeks.198 | ![]() | O |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Consensus statements . | Class . | Evidence . |
---|---|---|
A chest X-ray (postero-anterior and if possible lateral) should be performed in all patients after lead implantation and before discharge to rule out pneumothorax and document lead position. | ![]() | E |
Patients can be mobilized freely after device implantation once they have recovered from sedation. | ![]() | E |
Compression using sandbags, tapes or vests can be useful to avoid haematoma.184–186 | ![]() | O |
Patients do not need to restrict arm movements after device implantation, as this has not been shown to reduce risk of lead dislodgment and may increase shoulder pain.196 | ![]() | O |
The wound should be properly covered for 2–10 days, ideally with a waterproof dressing. | ![]() | E |
After discharge, patient-initiated consultation in case of problems may be sufficient in most cases (i.e. instead of routine wound inspection).197 | ![]() | O |
Patients should be seen in-office within 2–12 weeks.198 | ![]() | O |
Consensus statements . | Class . | Evidence . |
---|---|---|
A chest X-ray (postero-anterior and if possible lateral) should be performed in all patients after lead implantation and before discharge to rule out pneumothorax and document lead position. | ![]() | E |
Patients can be mobilized freely after device implantation once they have recovered from sedation. | ![]() | E |
Compression using sandbags, tapes or vests can be useful to avoid haematoma.184–186 | ![]() | O |
Patients do not need to restrict arm movements after device implantation, as this has not been shown to reduce risk of lead dislodgment and may increase shoulder pain.196 | ![]() | O |
The wound should be properly covered for 2–10 days, ideally with a waterproof dressing. | ![]() | E |
After discharge, patient-initiated consultation in case of problems may be sufficient in most cases (i.e. instead of routine wound inspection).197 | ![]() | O |
Patients should be seen in-office within 2–12 weeks.198 | ![]() | O |
E, evidence and expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
Acknowledgements
The authors thank the EHRA Scientific Document Committee: Dr Nikolaos Dagres, Dr Serge Boveda, Dr Kevin Vernooy, Prof. Zbigniew Kalarus, Prof. Gulmira Kudaiberdieva, Dr Georges H Mairesse, Prof.Valentina Kutyifa, Prof. Thomas Deneke, Prof. Jesper Hastrup Svendsen, Dr Vassil B Traykov, Prof. Arthur Wilde, Prof. Frank R. Heinzel.
Conflict of interest: A.A. is a consultant to Boston Scientific, Backbeat, Biosense Webster, Cairdac, Corvia, Microport CRM, EPD-Philips, Radcliffe Publisher. He received speaker fees from Boston Scientific, Medtronic, and Microport. He participates in clinical trials sponsored by Boston Scientific, Medtronic, EPD-Philips. He has intellectual properties with Boston Scientific, Biosense Webster, and Microport CRM. H.B. has received speaker honoraria from Biotronik and Medtronic and has received institutional fellowship support and research grants from Abbott, Biotronic, Boston Scientific, Medtronic, and Microport. J.-C.D. declares honoraria for lectures, research and travel grants from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. C.J.L. is a consultant to Medtronic and Philips Medical, and has received honoraria from Convatec and Abbott Medical, and research support from Boston Scientific. C.S. declares payment to his institution related to his activity as speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member from Angiodynamics, Medtronic, Spectranetics, Biotronik, Liva Nova (Sorin) and Cook Medical and departmental or institutional research funding from Cook Medical. K.V. is consultant for Medtronic and Abbott. None of the other authors report any conflicts of interest.
References
WHO. Global Guidelines for the Prevention of Surgical Site Infection. WHO Document Production Services,